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Abstract 
While considerable research exists on female HPV vaccine acceptance, research is needed to 
clarify factors that facilitate vaccine uptake among boys and men. The benefits of male HPV 
vaccination exist on an individual and community level. Male HPV vaccination provides 
personal health protection to recipients, and can provide female health protection by minimizing 
transmission of HPV to sexual partners.  As such, male vaccine acceptance may b enhanced by 
emphasizing both altruistic motives (female health protection) and personal health benefits. A 
sample of college-age men (N = 200; M age = 19.3; 31% Non-White) completed computer-
administered surveys and were presented with one of four informational interventions that varied 
in the inclusion or exclusion of altruistic motives and in terms of the extent to which male 
specific HPV-related illnesses and vaccine benefits were stressed. HPV vaccine acceptance was 
assessed immediately following the intervention with items assessing vaccine interest and 
willingness to receive it.  Consistent with predictions, those who received the interve tion 
emphasizing both altruistic motives and male specific information endorsed the great st vaccine 
acceptance (M = 3.6, SD = 1.0). Additionally, perceived HPV susceptibility and stigmatization 
concerns toward the vaccine emerged as significant predictors of vaccine aeptance. Findings 
suggest that provider-based and community level interventions that stress both altruistic motives 
and personal health benefits of vaccination may enhance HPV vaccine uptake among young 
men. 
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Enhancing Male HPV Vaccine Acceptance: The Role of Altruism and Awareness of Male 
Specific Health Benefits 
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
in the world (Baseman & Koutsky, 2005). High risk subtypes of HPV are causally linked to 
cervical cancer in women and genital warts in both men and women. Papanicolau (pap) smear 
screening programs for women have reduced the incidence of and mortality associated with 
cervical cancer in industrialized nations. Nonetheless, HPV contributes to approximately 4,000 
cervical cancer deaths in the United States and 250,000 worldwide each year (World Health 
Organization, 2010). Although cervical cancer is by far the most serious health concern linked to 
HPV, recent findings confirm that HPV is also associated with increased risk fo  oropharyngeal 
cancer in both men and women (Fakhry & Gillison, 2008).  Collectively, HPV infections are 
associated with significant morbidity and account for a high level of health care expenditures. In 
2000, it was estimated that the lifetime financial costs associated with HPV disease among 
young adults in the U.S. was $3.9 billion (Zimet, Shew & Kahn, 2008).  
Efforts to reduce the incidence of cervical cancer and other HPV-related illn sses 
received a major boost in 2006 with the introduction of Gardasil, a vaccine shown to be effective 
in preventing four of the highest risk subtypes of HPV linked to cervical cancer d genital 
warts.  Although developed initially for use only in women, Gardasil was recently approved by 
the Food and Drug Administration (FDA) and recommended by the Advisory Committee on 
Immunization Practices (ACIP) for use in boys and men.  Male HPV vaccination has the 
potential to reduce male to female transmission of HPV and decrease men’s risk for several 
HPV-related illnesses, including genital warts and several forms of oral, penile and anal cancers 
(Backes, Kurman, Pimenta & Smith, 2009; Palefsky, 2010; Smith et al., 2007). As such, 
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widespread uptake of Gardasil in both men and women could dramatically reduce the preval nce 
of HPV-related illnesses. 
Despite the potential for public health benefit, current national surveys show that only 
49% of adolescent girls ages 13 to 17 have received at least one dose of the HPV vaccine, while 
only 32% have completed the three dose regimen. Among the same age cohort, only 1% of boys 
have received the vaccine to date, according to Centers for Disease Control and Prevention 
(CDC) catchment data (CDC, 2011). Low uptake of the HPV vaccine is due in part to the fact 
that HPV vaccination is not mandated in the U.S. and is often not covered by health insurance 
policies. In fact, vaccination rates in the United Kingdom and Australia, where t  vaccine is 
paid for through government funds but not mandated, are over 80% (Peres, 2010).  
Research also suggests that psychosocial barriers contribute to low vaccine uptake. For 
example, research involving female adolescents and their parents confirms that low perceived 
risk for HPV infection and cervical cancer, low perceived vaccine effectiveness, low HPV 
knowledge, and vaccine safety concerns are associated with decreased interest i  vaccination 
(Brewer & Fazekas, 2007; Jacob, Bradley & Barone, 2005). Past research on psychosocial 
barriers to HPV vaccination has focused primarily on vaccine uptake among youn w men and 
their parents (for reviews, see Brewer & Fazekas, 2007; Zimet, 2005). Research on male 
acceptance of the HPV vaccine is limited, with only 13 studies investigating male vaccine 
acceptance in the U.S. Moreover, no studies on male vaccine acceptance have been published 
since FDA approval of the HPV vaccine for men.  
Accordingly, the current study was conducted to investigate factors that influence male 
willingness to seek vaccination. Focusing on a college sample of unvaccinated men, the study 
utilized an experimental design to address three primary aims:  (a) to examine whether a brief 
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intervention can enhance altruistic motives for vaccination (i.e. reducing women’s risk for 
cervical cancer) and subsequently influence vaccination acceptance among men, (b) to 
investigate the effect of highlighting male specific HPV-related health conditions and vaccine 
benefits on male vaccine acceptance; and (c) to expand current understanding of the influence of 
other psychosocial factors on HPV vaccine acceptance among men. The following sections 
present the global and domestic effects of HPV, the development and uptake of the HPV 
vaccine, as well as extant findings on vaccine acceptance among young women and their parents. 
The role of altruism and intervention message content in potential male vaccination s discussed 
and introduced as variables in the proposed experimental design. 
HPV Transmission and Epidemiology 
Human papillomavirus is currently the most common type of sexually transmitted 
infection in the world (Baseman & Koutsky, 2005; Trottier & Franco, 2006). HPV is more easily 
transmitted than other common STIs, requiring only skin to skin contact. In addition to vaginal 
intercourse, oral, anal, and digital-vaginal sex are all possible routes of transmission (Cox, 2006; 
Trottier & Franco, 2006). In the U.S., it is estimated that approximately 20 million Americans 
are infected with HPV at any given time (Cox, 2006). Modeling estimates pose that more than 
80% of sexually active females will be infected by HPV prior to the age of 50 (Myers, McCrory, 
Nanda, Bastian, & Matchar, 2000).  Representative, population-based sample studies fo nd 
prevalence rates to be 27%, with the highest rates of infection in young adult women (Manhart et 
al., 2006; Dunn et al., 2007).  HPV prevalence rates are challenging to determine because there 
are often no manifest symptoms and infections typically clear without treatment. Nonetheless, 
the best available estimates suggest that HPV is most prevalent among sexually active females 
under 25 years of age, and prevalence decreases with age.  
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 Human papillomavirus exists as more than 120 different strains, of which over 40 
account for genital HPV. Strains are classified as high risk (HR-HPV) and low risk (LR-HPV), 
with high-risk strains associated with the development of cervical cancer, oth  neoplasms, or 
squamous cell carcinomas. HPV types 16 and 18, in addition to 13 other types, are considered 
highest risk subtypes that are causally linked to cervical cancer (Baseman & Koutsky, 2005). 
Types of HPV 6 and 11 are lower risk, but nonetheless carry undesirable outcomes because they 
are causally linked to genital warts and low grade squamous intraepithelial lesions (LSIL) in the 
cervix (Trottier & Franco, 2006).  
Health Impact of HPV Among Women 
HPV represents a significant health care burden in the U.S. An estimated 6.2 million new 
cases of HPV-related illnesses linked to cervical abnormalities require diagnosis, management 
and follow up each year (Trottier & Franco, 2006). Among these, the most severe consequence 
and greatest health burden is cervical cancer. In the U.S., there are approximately 12,000 new 
cervical cancer cases annually and 4,000 deaths (Ferlay et al., 2010). Worldwide, cervical cancer 
is the second most common cancer in women, second only to breast cancer. An estimated 
275,000 deaths occur each year across the globe and more than 85% of these are in developing 
countries where screening and treatment resources are lacking (Baseman & Koutsky, 2005; 
Ferlay et al., 2010; Trottier & Franco, 2006). Indeed, cervical cancer causes the highest number 
of female deaths due to cancer in developing countries (Pisani, Parkin, Bray & Ferlay, 1999) and 
accounts for the single greatest number of years lost to cancer in the developing w rld (Agosti & 
Goldie, 2007).  
HPV also causes genital warts, a condition that affects an estimated 1% of sexually active 
individuals at any given time (Koutsky, 1997). Clinical symptoms of genital warts include 
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itching, burning, tenderness at site as well as bleeding or discharge. Also, studies have found 
genital warts to produce feelings of anxiety, embarrassment, shame and decrease in sexual 
enjoyment for those infected (Insinga, Dasbach, & Myers, 2003). Insinga, Dasbach and Myers 
(2003) conducted a study using Medstat data from 2000 which found estimates indicating an 
annual health and economic health care burden of 330,000 cases of genital warts and $140 
million for privately insured populations. Specifically they found the cost for one episode of 
treatment for a female to total $404. Treatment of genital warts focuses on rm val of visible 
lesions or plaques that cause physical or psychological distress. However, treatment methods 
including patient applied topical medicines and surgical removal do not necessarily erad cate 
HPV infectivity.  
Health Impact of HPV Among Men 
To date, most research on the health impact of HPV has focused on women. In addition 
to serving as the primary transmission vector of HPV to women, there are in fct several serious 
HPV-related health conditions that affect men.  HPV 6 and 11 account for more than 90% of 
anogenital warts and laryngeal papillomatosis in men. Laryngeal papillomatosis involves the 
formation of warts on the laryngeal, tracheal, bronchial, or other respiratory mucosa. Difficulty 
breathing and swallowing as well as hoarseness and chronic coughing occur in individuals who 
develop these tumors (Smith et al., 2007). Prevalence studies show that for adults, the male o 
female prevalence ratio is approximately 4 to 1, indicating further burden on men caused by 
HPV (National Institute of Deafness and other Communication Disorders, 2010). 
Recent findings also confirm a linkage of oral HPV to the onset of head and neck 
squamous cell carcinomas (HNSCC) in men. While alcohol and tobacco use are well established 
risk factors of HNSCC, HPV infectivity has more recently been identified as an agent in the 
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pathogenesis of head and neck cancers.  For example, individuals positive for HPV 16 have been 
found to confer a 2 to 3 fold increase in risk for HNSCC, as well as a greater than 14 fold 
increase in risk of oropharyngeal cancer as compared to HPV negative individuals. Men are 
disproportionately affected by these HPV-related cancers in the U.S. Approximately 5,700 men 
are diagnosed with HPV associated HNSCC each year, as compared to 1,700 women (Watso  et 
al., 2008). Case controlled studies have shown that the presence of oral HPV infection can be 
associated with a six fold increase in risk for oral cancer. For men, the incidence of HPV 
associated squamous cell carcinomas in the oropharynx and oral cavity account for 23%of all 
HPV associated cancers (Kreimerm, Clifford, Boyle & Franceschi, 2005). HPV has also been 
linked to the development of tonsil cancer (Fakhry & Gillison, 2008).  
 Moreover, HPV has been implicated in the development of penile cancer in men.  
Medical understanding of penile cancer etiology is more limited than other cancer types.  Two 
different etiologies are hypothesized for the development of penile cancer, o e linked to HPV 
positivity and one that requires other factors in pathogenesis (Rubin, Kleter & Zhou, 2001). In a 
review of the medical literature, Backes and colleagues (2009) examined 30 studies with over 
1,200 cases of squamous cell carcinoma which account for 95% of penile cancers.  Their goal 
was to determine the prevalence on HPV DNA in invasive penile cancer. They found the 
presence of HPV in approximately 50% of the cases reviewed.  HPV types 6, 16, and 18 were
the most prevalent types of HPV found in penile squamous cell carcinomas.  Such findings 
firmly suggest that quadrivalent vaccines such as Gardasil have the potential to reduce over 
three-fourths of HPV positive penile squamous cell carcinomas (Backes, Kurman, Pie ta & 
Smith, 2009).  
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As research continues to demonstrate a causal link between HPV and different types of 
cancers that affect men, the argument for male vaccination can be supported by its importance at 
the individual level. As discussed, HPV 6 and 11 account for over 90% of anogenital warts and 
laryngeal papillomatosis in men. HPV 16 and 18 contribute to the pathogenesis of head and neck 
cancers. These four strains of HPV, all prevented by the HPV vaccine Gardasil, lead to 
considerable male suffering, although at relatively low prevalence rates. With respect to the most 
severe health consequences of HPV for men, diagnoses such as penile, anal and head and neck 
cancers are fairly infrequent in the U.S. For example, it is estimated that only 800 men are 
diagnosed with HPV-related penile cancer annually and penile cancers account for only 0.1% of 
deaths from cancer among males in the United States. HPV-related head and neck canc rs are 
more prevalent than penile cancer (though still relatively rare), with approximately 5,700 men 
being diagnosed with HPV-related head and neck cancers per year in the United States (CDC, 
2010).  
Thus, while HPV is most commonly linked to health-related concerns in women, 
available data also point to potential health benefits of HPV vaccination to prevent mal  specific 
health concerns. However, given the relatively low prevalence rates for male specific health 
concerns and the perception that HPV is primarily a women’s health issue, promoting ale 
vaccine acceptance may require a dual emphasis on personal health benefits as w ll as an 
emphasis on the potential benefits of male vaccination for women.  
The HPV Vaccine 
Up until recently, the primary approach to reducing the impact of HPV-related iln sses 
in the U.S. has been the Papanicolau (pap) test. Routine pap smears have proven highly effective 
in alerting women to cervical abnormalities that, with early detection, can be succ ssfully 
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treated.  However, pap smears are a screening tool not readily available in developing countries 
where the devastation associated with cervical cancer is greatest. Th  resources, expertise, and 
the necessity of repeated screening at frequent intervals, have served as major barriers to 
cytology-based screening in most poor countries (Agosti & Goldie, 2007).   
The landscape for the prevention of cervical cancer and other HPV-related illnesses 
experienced a major change with the introduction of Gardasil in 2006 for women and in 2009, 
with the approval of Gardasil for boys and men.  The availability of an HPV vaccine provides 
tangible hope for a reduction in health burdens associated with HPV in the U.S. and worldwide. 
It has been projected that widespread uptake of HPV vaccination in conjunction with continued 
cervical screenings could lead to as high as a 76% lifetime reduction in cancer-related deaths 
attributable to HPV and a 50% reduction in cervical abnormalities (Adams, Jasani & Fiander, 
2007).  
In 2006, Merck & Co., Inc. received approval from the U.S. Food and Drug 
Administration to administer their quadrivalent human papillomavirus recombinant vaccine to 
females ages 9 to 26 (U.S. Food & Drug Administration, 2006). Gardasil is a quadrivalent 
vaccine that protects against four different strains of HPV.  Strains 6 and 11 are low risk strains 
that cause 90% of genital warts and strains 16 and 18 are responsible for 70% of cervical ancer 
cases (Adams, Jasani & Fiander, 2007; Villa et al., 2005).  The vaccine is administered in three 
doses, at 0, 2, and 6 months.  Clinical trials suggest that immunity post vaccination is greater 
than four years, although it is not yet known whether a booster vaccination will be required 
(Adams et al., 2007). Mathematical modeling analyses of the three dose regimen have predicted 
99% of women could have nearly life- long detectable anti-HPV 16 levels, indicating long 
lasting, robust immune memory and decreased chance of booster requirements (Ault, 2007). 
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 In 2002, Merck began conducting a series of clinical trials on the quadrivalent vaccine. 
The Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I) double 
blind study randomized 5,445 women between the ages of 16 and 24 to receive the vaccine or a 
placebo and they were followed for approximately three years.  The vaccine was found to be 
100% effective in preventing vaginal, vulvar, perineal and perianal intraepithelial lesions 
associated with HPV 16 and 18 in never before infected women. In women previously exposed 
to the HPV types, the vaccine was found to be 73% effective for preventing anogenital or vaginal 
lesions and 55% effective for preventing cervical lesions (Garland et al., 2007).  The larger 
FUTURE II study employed the same protocol and the vaccine prevented 98% of cervical 
intraepithelial neoplasia in never before infected women. The clinical trials found relatively few 
adverse side effects with the most common being irritation at the injection site (FUTURE  II, 
2007; Garland et al., 2007).  
HPV Vaccine Efficacy in Men 
As noted, the HPV vaccine, Gardasil, was recently approved for use in men following 
encouraging results of phase III efficacy trials. In 2008, Merck & Co. completed a large scale 
study of male vaccination on 4,065 men and boys, ages 16 to 26 (Norris, 2008). The double blind 
study included two groups, one that received the vaccine or placebo, at day one, two months and 
six months and were followed for 36 months in total.  No participants had any genital lesions or 
history of warts prior to enrollment.  Results showed that only three cases of genital warts 
occurred in the vaccine group versus 31 cases in the placebo group.  Therefore, Gardasil was 
found 90% effective in reducing lesions.  Also, there were no serious side effects stemming from 
HPV vaccination among participants in the trial, other than irritation at the injection site.  These 
findings provide evidence of vaccine efficacy among males and point to a promising approach to 
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reducing HPV-related health concerns in men. With widespread male uptake of the vaccin , 
reduced HPV infections in men would also provide indirect health benefits to women by 
reducing male to female HPV transmission, thereby reducing women’s risk for cervical cancer 
and other HPV-related health concerns.  
HPV Vaccine Uptake in the United States 
 Female uptake of the vaccine remains a focus of U.S. media and public health and thus 
vaccine efficacy and uptake data are focused primarily on girls and women. Data from the 2010 
National Immunization Survey by the Centers for Disease Control and Prevention indicates that 
49% of adolescent girls ages 13 to 17 have received at least one dose of the HPV vaccine, while 
only 32% have completed the three dose regimen (CDC, 2011). These rates are higher than 
previous years, however remain disappointing as a public health effort. The 2010 survey also 
conveyed the first uptake rates for boys and men, following FDA approval. Notably low HPV 
vaccine uptake rates indicated that only 1% of boys within the 13 to 17 year old age range had 
received the vaccine (CDC, 2011). An important and understudied question concerns the extent 
to which young men are interested and willing to take the HPV vaccine. While most HPV 
vaccine acceptance research has focused on females, there is now a growingliterature on male 
vaccine acceptance. The following reviews research on both female and male vaccin  acceptance 
and uptake. 
HPV Vaccine Acceptance 
While efficacy, safety, access, and costs are vital to shaping public approval and upt ke 
of a vaccine, psychological factors also play an important role in vaccination decisions. Relative 
to other routine vaccinations, initial roll-out of the HPV vaccine in the U.S. was hampered by 
controversy (Herzog, Huh, Downs, Smith & Monk, 2008; Zimet et al., 2008). An initial push by 
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a number of states to include HPV as a required vaccine for school attendance was mt ith 
considerable resistance from organizations that voiced a variety of concerns, including the 
possibility that vaccination might promote promiscuity and tacit approval of sexual beh vior 
among young adolescents (Haber, Marlow & Zimet, 2007). Because the HPV vaccine is not 
mandated, adolescents (and their parents) must request receipt of the vaccine in order to receive 
it. For some, the decision to vaccinate may be complicated by the fact that the vaccin  prevents a 
sexually transmitted infection, but is recommended for children who are not yet sexually active. 
Therefore, parents and their children are placed in a decision making situation h  may prove 
more difficult than other vaccination decisions. Thus, attitudes and beliefs about the HPV 
vaccine among parents and individuals in the target vaccination age range are lik ly to be 
primary determinants of adolescent vaccination. In the next section, the current lite ature on 
HPV vaccine acceptance is presented. Specific correlates of and barriers to vaccine uptake are 
discussed. 
HPV Vaccine Acceptance Among Girls  
Since the introduction of the HPV vaccine, the literature on vaccine acceptance and 
uptake has grown rapidly. A unique variable that distinguishes this area of study from past 
research on vaccination is that this vaccine prevents an STI and is recommended for pr -sexually 
active girls and boys. In both the media and realm of public health, concerns regarding 
promotion of a vaccine that could be perceived as promoting sexual activity have been rais d 
(Haber et al., 2007). Parent perceptions of the vaccine have been highlighted as an importat area 
of research, since the vaccine is recommended for young girls and boys who defer vaccination 
decisions to their parents. Therefore, research has utilized both parent and youth populations.  
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Correlates of vaccine acceptance among girls.  Research on HPV vaccine acceptance 
has primarily been descriptive and correlational in nature.  Demographics, perceptions of vaccine 
efficacy and safety, HPV knowledge, and attitudes towards the vaccine have been most 
extensively studied with respect to acceptance and uptake. Additionally, HPV vaccine delivery 
and perceived susceptibility to contracting HPV have emerged as variables of interest (Brewer & 
Fazekas, 2007; Zimet et al., 2008).  
The following reviews the extant literature, highlighting female correlates of HPV 
vaccine acceptance, as well as barriers to vaccination that have been identified in research. First 
we focus on the role of HPV knowledge as well as perceived susceptibility to contracting the 
infection in vaccination decisions. Physician recommendation in HPV vaccination is also 
discussed. Next we review both structural barriers and individual concerns regarding 
vaccination. A discussion of vaccine safety concerns and implications for teen sexual activity 
follows.  
HPV knowledge. Prominent health behavior models specify that knowledge or 
information concerning a target health outcome contributes to decisions regarding initiation of 
preventive behaviors (e.g., Fisher & Fisher, 1992). In the context of HPV vaccination 
acceptance, a number of studies confirm that (a) HPV knowledge is typically low and (b) people 
who are more knowledgeable about the causes and consequences of HPV infection are often 
more willing to consider vaccination (Black, Zimet, Short, Sturm & Rosenthal, 2009; Ferris, 
Waller, Owen, & Smith, 2007; Kahn, Rosenthal, Hamann, & Bernstein, 2003). In the early 
1990’s, studies conducted with college students showed knowledge of HPV to be as low as 15% 
(Vail-Smith & White, 1992). However, with the advent of the HPV vaccine and media marketing 
to promote vaccination, a modest improvement in HPV knowledge has been observed across 
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several studies (e.g., Ferris et al., 2008; Gerend & Magliore, 2008).  For example, in a sample of 
male and female college students surveyed shortly after FDA approval of the vaccine, 78% 
reported having heard of HPV and 87% of participants earned a score of 4 or higher, out of 6 n 
a basic HPV knowledge test (Gerend & Magliore, 2008).  
Several studies confirm that HPV knowledge is positively associated with HPV vaccine 
acceptance. Ferris and colleagues (2008) found that understanding that HPV causes cervical 
cancer and awareness of being at risk for HPV infection were positive correlates of vaccine 
acceptance among adult women. A study using a large, national sample highlighted knowledge 
differences between girls and women who had received the vaccine and those who had not. 
Findings showed that compared to unvaccinated females, those who had been vaccinated were 
more likely to know that the HPV vaccine protects against cervical cancer (Caskey, Lindau & 
Alexander, 2009). Also, vaccinated females reported receiving HPV information from primary 
care physicians significantly more so than unvaccinated females who endorsed school as their 
major source of HPV knowledge. Finally, in a sample of parents of unvaccinated daughters, 
Fakekas, Brewer and Smith (2008) found that higher HPV knowledge was associated with 
stronger intentions to vaccinate daughters.  
Although most studies support an association of increased HPV knowledge and greater 
vaccine acceptance, a study conducted by Gerend & Magliore (2008) failed to fin  a significant 
correlation between HPV knowledge and vaccine interest among college-age women.  
Nonetheless, there is at least moderate support for a linkage of HPV-related knowledge to HPV 
vaccine acceptance. Providing education about HPV and HPV-related health concerns is likely to 
be an important element in efforts to increase HPV vaccination.   
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Perceived HPV severity and susceptibility. Another correlate of HPV vaccine acceptance 
that has emerged in the literature is perceived susceptibility to HPV infection (Black et al., 2009; 
Gerend, Lee & Shepherd, 2007; Gerend & Magliore, 2008; Burke, Smith, White, Baker & 
Mitchell, 2010). Consistent with other areas of vaccination research, findings confirm that 
vaccine acceptance and uptake is strongest among those who perceive HPV to have severe health 
consequences and who perceive themselves to be personally vulnerable to HPV infection. For 
example, Gerend and Magliore (2008) found that perceived risk for HPV infection was 
independently associated with HPV vaccination interest. Similarly, perceiv d susceptibility to 
HPV was associated with HPV vaccine acceptance in a sample of underserved wom n in 
community clinics in the South (Gerend et al., 2006).  
 Physician recommendation. Physician recommendation has also been cited as an 
influential motivator of HPV vaccine acceptance (Brewer & Fazekas, 2007; Caskey et al., 2009). 
A recent study found that 100% of parents who reported vaccinating their daughter cited 
receiving a physician’s recommendation, compared to the 53% of parents with unvaccinated 
daughters (Gerend, Weibley & Bland, 2009). In a sample of rural and urban parents, doctor’s 
recommendation was one of the strongest correlates of HPV vaccine initiation (Reiter et al., 
2009).  Additionally, in a cross-sectional survey of girls and young women ages 13 to 26 years, 
significant differences emerged between vaccinated and unvaccinated girls in that vaccinated 
girls more frequently reported a healthcare provider as their most common source of HPV 
vaccine information (Caskey et al., 2009).  Similar research supports the findings that physician 
recommendation holds much influence over parents and adolescents alike when making a 
vaccination decision such as receiving the HPV vaccine (Brewer & Fazekas, 2007; Dempsey, 
Davis, Zimet & Koutsky, 2006; Kahn et al., 2003). 
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Sexual activity status. Much of the controversy that surrounds the HPV vaccine rests on 
the notion that encouraging a method to prevent a sexually transmitted infection may be
perceived as condoning sexual activity. The concern that HPV vaccination may promote 
promiscuity has been described in both the popular press (Gibbs, 2006) and scientific review 
articles (Zimet et al., 2008). Nonetheless, empirical findings have been mixed in supporting the 
hypothesis that promiscuity concerns serve as a barrier to vaccination. In several tudies, only 6 
to 12% of parents endorsed the belief that vaccine-related promiscuity was a barrier to vaccine 
uptake (Brewer & Fazekas, 2007; Constentine & Jerman, 2007; Davis, Dickman, Ferris, & Dias, 
2004; Zimet et al., 2005). While this is not a relevant concern for teenagers and young adults 
deciding to vaccinate, this line of research is important moving forward, as vaccination 
recommendations are for girls and boys prior to sexual debut. 
Perceived vaccine safety. Vaccine safety, particularly among parents deciding to 
vaccinate their daughters, has also emerged as a barrier to acceptability (Brewer & Fazekas, 
2007; Davis et al., 2004; Dempsey et al., 2006). Empirical evidence affirms that, apart from 
minor side effects, the vaccine is safe. The CDC and FDA currently utilize thre  systems through 
which to monitor any adverse effects of vaccine administration. To date, these programs report 
approximately 32 million doses of Gardasil administered and approximately 1,300 reported 
adverse events deemed serious by the Vaccine Adverse Event Reporting System (VAERS). 
However, it is explicitly noted that these events have no proven causal association w th the 
vaccine. Medical experts review each case and to date no medical pattern related to the vaccine 
has been identified (CDC, 2010). 
Despite the objective safety data that exists on the HPV vaccine, parental concerns about 
vaccine safety remain common. Two studies of parental attitudes toward children receiving the 
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HPV vaccine found that vaccine safety concerns were a significant predicto  of decreased 
vaccine acceptance (Constantine & Jerman, 2007; Dempsey et al., 2006). In addition to paretal 
reactions to vaccine safety, girls and young women have been found to endorse similar safety 
concerns. A study surveying girls and women 13 to 26 years old found that vaccine safety 
concerns were the second most important barrier to receiving the HPV vaccine (Cask y et al., 
2009).  
 Summary.  HPV vaccine acceptability has been a growing area of research in medical, 
public health, and psychology arenas. Research that seeks to identify motivators and barriers to 
HPV vaccination is of importance, as such knowledge can be used to inform the development of 
interventions to increase vaccine uptake. Findings concerning greater HPV knowledge, increased 
perceived susceptibility to HPV and physician recommendation have emerged as factor  that 
facilitate vaccine acceptance (Black et al., 2009; Brewer & Fazekas, 2007). Findings also suggest 
that concerns about teenage promiscuity, and vaccine safety concerns may serve as barriers to 
acceptance. Findings considered thus far have focused primarily on data regarding female 
vaccination. Next, literature on male HPV vaccination is reviewed.  
Male Vaccination: Emerging Literature 
Despite the rapid influx of studies on female HPV vaccine acceptance and uptake, 
research on male vaccination acceptance has only recently begun to emerge. To some extent, the 
decision to receive the HPV vaccine presents a different set of issues for males compared to 
females. The most significant contribution of the vaccine is its potential to prevent cervical 
cancer, a disease only threatening to women. The health risks of HPV for males are p rceived as 
considerably lower. The actual male health risks represent significant he lth concerns for men, 
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but are less prevalent and severe compared to cervical cancer (Barnholtz-Sloan et al., 2008; 
Ryerson et al., 2008).  
Men are also carriers of HPV and therefore serve as vectors in the transmission of HPV 
to women. As such, male vaccination decisions may also be linked to the belief that HPV 
immunity in men can reduce women’s risks for cervical cancer and other health concerns. 
However, little information is available concerning the extent to which men’s interest in 
vaccination can be influenced by the belief that vaccination can help to protect women fr 
serious health concerns.  
In the U.S., there have been a limited number of published studies that focus on male 
HPV vaccine acceptance. Similar to the female literature, studies hav utilized both parent and 
youth populations and have investigated factors that influence male perceptions of HPVand 
acceptance of the HPV vaccine.  The following reviews the role of HPV knowledge, perc ived 
HPV severity and susceptibility, as well as demographic and sexual behavior variables 
associated with male vaccine acceptance. Finally, several studies are reviewed that suggest that 
providing information about self-protection a d female partner protection may enhance male 
vaccine acceptance.  
HPV Knowledge. Similar to findings regarding female knowledge of HPV, recent studies 
confirm that male knowledge concerning HPV is generally low, though has increased somewhat 
since the introduction of Gardasil in the media. Prior to FDA approval of the vaccine for females, 
McPartland and colleagues (2005) found HPV knowledge to be generally low among a college
age sample of men, with approximately 50% reporting having heard of HPV. Following 
Gardasil’s entry to the U.S. market, Gerend and Barley (2009) surveyed college aged males and 
found that 83% reported having heard of HPV. However, understanding of the connection 
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between HPV and genital warts and anogenital cancers was low (28% and 23% respectively). 
HPV knowledge was found to be significantly correlated with HPV vaccine acceptability among 
the males in the study. Other studies investigating male HPV vaccine acceptance have yielded 
similar findings showing increased familiarity with HPV as well as an association between HPV 
knowledge and vaccination interest among men (Ferris et al., 2009; Jones & Cook, 2008; Reiter, 
Brewer & Smith, 2010). 
Perceived HPV severity and susceptibility. As with the literature on female HPV vaccine 
acceptance, researchers have also examined the role of perceived severity and susceptibility to 
HPV as factors that may be relevant to male vaccine acceptance. Studies conducted prior to FDA 
approval of Gardasil indicated that college age males did not perceive HPV to be a severe 
disease, nor did they believe themselves to be highly susceptible to HPV infection (Boehneret 
al., 2003; McPartland et al., 2005). Studies conducted following vaccine approval yield similar
findings, showing that males typically do not endorse HPV as a severe health concern. 
Nonetheless, perceptions of susceptibility to HPV have emerged as consistent corr lates of 
vaccine acceptance in recent studies involving males (Crosby, DiClemente, Salazar, Nash & 
Younge, 2011; Gerend & Barley, 2009; Jones & Cook, 2008; Reiter et al., 2010).  
Researchers have also assessed male perceptions regarding HPV-related risks for 
females. McPartland and colleagues (2005) asked male college students to indicate how severe 
they thought genital HPV infection was for themselves and for their female partners. On a five 
point scale, males endorsed an average score of 2.4 for personal severity of the STI, while they 
assigned their female partners a score of 3.4. They were also asked how likely infection was for 
themselves and their female partners. Males did not perceive women to be any more susceptible 
to contracting HPV relative to their own risk for infection. These findings lend insight into male 
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perceptions of female sexual health. Although college age males did not believe their f male 
partners to be more susceptible to HPV, they correctly perceived that HPV-related health 
concerns are more severe for females, relative to males.  
Sexual behaviors and demographic data. Emerging research on HPV vaccine 
acceptance among men has focused on sexual risk behaviors as potential predictors of 
acceptance, though findings have been mixed. In a sample of college age men, significantly 
greater HPV vaccine acceptance was found among those who reported recent sexual activity as 
well as those who reported multiple sex partners over the past three months (Crosby, 
DiClemente, Salazar, Nash & Younge, 2011). Several studies have yielded similar find ngs, 
indicating higher levels of vaccine acceptance are associated with sexual activity and multiple 
partners (Crosby et al., 2012; Ferris et al., 2009; Gerend & Barley, 2009; Katz, Krieger & 
Roberto, 2011). 
Research on male vaccine acceptance has been conducted outside of the scope of colleg
students as well. A variety of potential correlates of vaccine acceptability were investigated in a 
study of 571 men ages 18 to 45. Participants completed a survey that included an assessment of 
men’s reasons for wanting or not wanting to receive the HPV vaccine. Results showed tat, 
compared to white men, African American men were more likely to oppose vaccination. In 
addition, men who were not currently sexually active were more likely to want the vaccine 
relative to those who were sexually active. Factors that were found to be most strongly 
associated with male intentions to receive the vaccine included physician recomm ndation, 
insurance coverage for the vaccine, and research-based evidence of vaccine s fety and efficacy 
in (Ferris et al., 2009). 
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Male and female health benefits of male HPV vaccination. With men serving as the 
primary transmission vector of HPV to women, the potential female advantages of vaccinating 
men against the STI have been cited throughout the literature (Friedman et al., 2011). While 
vaccinating women in an effort to decrease the prevalence of cervical cancer is worthwhile, 
concurrent efforts to vaccinate men to decrease the transmission and incidence of the virus would 
provide a more rapid means of reducing the prevalence of cervical cancer (Elbasha, Dasbach & 
Insinga, 2007; Hughes, Garnett & Koutsky, 2002; Riedesel et al., 2005). Therefore, an important 
question concerns whether providing information about self-protection and female partn r 
protection can enhance vaccine acceptability among males.  
Previous research provides limited evidence to indicate that male concern for female 
sexual health may influence men’s health behaviors. Studies demonstrate that males perceive the 
consequences of HPV to be significant for their female partners and have subsequently shown 
male concern for female sexual partners to affect their personal health b havior intentions 
(Boehner et al.; Jones & Cook, 2008; McPartland et al., 2005). A previously cited study 
conducted by McPartland and colleagues (2005) found that a majority (95%) of male colleg  
student participants reported that if they were diagnosed with HPV, they would increase their 
condom use. More than half also reported that they would reduce their number of sexual partners
(54%) and encourage female partners to obtain routine pap tests (59%) following notice of an 
HPV diagnosis. Although the study did not assess men’s interest in the HPV vaccine, male’s 
willingness to endorse other protective sexual health behaviors suggests that protecting sexual 
partners may serve as a motivator in health behavior decision making. 
A study conducted by Jones & Cook (2008) sought to investigate how emphasizing 
different protective health benefits of a hypothetical HPV vaccine would affect college student 
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ratings of vaccine acceptance. Findings revealed that vaccination intentions were higher among 
men when considering a fictional vaccine described as providing protection against both genital 
warts and cervical cancer compared to a vaccine described as preventing crv cal ancer alone 
(78% vs. 34%). The findings suggest that college age men may be most motivated by the 
prospect that their immunization will result in self-protection (against genital warts) and female 
partner protection. However, the study did not include a scenario offering only male benefits of 
vaccination, leaving unanswered the question of whether stressing female health benefits 
provides additive value relative to simply stressing male health benefits.  
Summary. Research on male vaccine acceptability confirms that many men are willing to 
consider vaccination and that factors such as HPV knowledge, perceived susceptibility to 
infection, and belief in personal health benefits of vaccination are influential in vaccine 
acceptance among men (Baer et al., 2002; Ferris et al., 2009; Gerend & Magloire, 2008; 
McPartland et al., 2005).  Furthermore, one study provides indirect evidence to suggest that 
messages regarding female protection from HPV-related illnesses could serve a  a motivator for 
male vaccination. 
Emerging Research Priority: Altruism as a Potential Motive for Male HPV Vaccine 
Acceptance 
As noted, concurrent vaccination of both males and females offers more rapid means of 
reducing the prevalence of cervical cancer in women, along with other potential h alth benefits 
for both men and women. An important and as of yet understudied question concerns the degree 
to which men’s willingness to consider the HPV vaccine can be enhanced by emphasizing the 
benefits of male vaccination for women’s health. Informational messages that promote altruism 
may bolster male interest in HPV vaccination. Although most health behaviors are adopted for 
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the purpose of self-protection, there are important exceptions. For example, smoking cessation 
programs emphasize reduced personal health risks, as well the benefits of reducing health risks 
to others through exposure to second hand smoke.  In the context of STI prevention, condom use 
figures prominently as a means of both self-protection and partner protection. Although the 
potential health benefits to women of male HPV vaccination are more remote relative to condom 
use, men’s decision to vaccinate against an STI might well be influenced by awareness that 
vaccination provides an opportunity for both self-protection and partner protection. The 
following reviews a limited literature regarding the potential role of altruism as a motive for 
vaccination.  
 Altruism can be considered a state of personal agency in which regard for another is the 
primary motivation, despite relatively little expectation of reciprocity or personal gain foreseen 
(Post, 2007). Though not widely studied, it is a concept that is implicitly invoked by many 
immunization programs worldwide (e.g., mumps, measles & rubella (MMR), purtussis, 
influenza). Applying ideals of altruism for some vaccines, such as tetanus, would have little 
benefit (Vernon, 2003). However, altruistic motives may be quite relevant in the context f 
vaccination decisions for prevention of STIs. By vaccinating against any disease that is spread by 
human contact, an individual decreases the chances that those around him will contractthe 
disease, thereby providing both self-protection, partner protection, and, potentially, community-
wide benefit. 
 The concept of altruism. Altruism has proven a challenging construct for researchers to 
understand since such behaviors defy the long held understanding of evolution and egoism which 
indicates that individuals will only act in ways that benefit the common good when the ac ion or 
outcome is in their best interest. However, researchers confirm that individuals act in purely 
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altruistic ways in both controlled research scenarios and in everyday life (Batson, 2011; 
Hoffman, 1981; Krebs, 1970). The empathy-altruism hypothesis has emerged out of social 
dilemma and game theories to provide a model of why and when individuals act in a way that 
serves the greater good in the absence of self-reward. 
 The empathy-altruism hypothesis poses that altruistic motivation occurs in situations that 
engender empathic reactions to another persons’ or groups’ circumstance. Empathy, from this 
perspective, is viewed as the emotional response to the perceived welfare of another. Studi s 
have found support for this theory by manipulating empathic concern in participants and placi g
them in social dilemmas. Findings have consistently shown individuals to be altruistically 
motivated in their actions when they experience empathy for another (Batson, 2011). An 
important distinction in this conceptualization of altruistic motivation is the focus n another 
person or group’s welfare. Consideration of individual and group welfare is especially voked in 
the realm of health. Therefore, it is likely that altruistic motivation mayoccur particularly in 
consideration of individual and group health.  
 Altruism as a motive for vaccination. The role of altruism has not been widely applied 
to health fields through research but particular areas call for such study. Vaccination is a topic 
that is highly relevant to the concept of altruistic motivation. Immunization pr grams serve to 
promote health at not only an individual level, but a population level. Herd immunity is the 
concept in which unimmunized members of a population acquire greater immunity to infecion 
based on the immunization of other members of the population (Hershey et al., 1994).  
Essentially, the more members immunized, the less the infection is able to transmi  through the 
population. The concept of herd immunity evokes the question of altruistic motivation serving to 
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encourage individual receipt of vaccination. However, as highlighted in what follows, there is 
very limited research investigating the role of altruism in vaccination. 
 Prior research regarding altruism and vaccination has revolved around the altruistic 
nature of participating in vaccine trials and health promotion research (Colfax et al., 2005; 
Nyamathi, Suhadev, Swaminathan & Fahey, 2007; Strauss et al., 2001; Suhadev et al., 2006; 
Williams, Entwistle, Haddow & Wells, 2008 ). This line of research has confirmed that altruism 
can serve as a motivating factor for individuals when deciding to participate in human 
immunodeficiency virus (HIV) vaccine trials. For example, Colfax et al. (2005) assessed motives 
for participation in a vaccine trial in a sample of men who have sex with men (MSM) and 
heterosexual women reporting high risk sexual and drug use behaviors. A large majority of 
participants cited altruistic reasons for trial participation. Ninety eight percent agreed that they 
enrolled “to help their community” (Colfax et al., 2005). Other cohort studies confirm the 
importance of altruism as a motive for participating in HIV vaccine trials (Bartholow et al., 
1997; Hays & Kegeles, 1999; Jenkinset al., 1998; Nyamanthi, Suhadev, Swaminathan & Fahey, 
2007).  
While HIV vaccine research suggests that altruistic motives may enhance people’s 
willingness to participate in vaccine research, these studies involve assessment of hypothetical 
willingness to vaccinate (since there is no HIV vaccine). Moreover, these studies hav  been 
descriptive in nature, only providing data on the percentage of individuals who endorse altrui m 
as a motive for participation. Nonetheless, such research points to the potential relevanc  of 
altruism in the context of HPV vaccination choices. 
 Altruism and HPV vaccination. To date, only two studies have applied principles of 
altruism to the question of male acceptance of the HPV vaccine. In Gerend and Barley’s (2009) 
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experiment, the authors sought to clarify differences in vaccine acceptability by comparing 
responses among participants who reviewed information that emphasized the self-protective 
benefits of the HPV vaccine versus participants who reviewed information that emphasized both 
self-protection and partner protection as benefits of vaccination. While not explicitly addressed 
as altruism, in the context of HPV and STIs in general, the concept of partner protection is 
related to that of altruism. Male college students were presented with one of two in ormational 
messages. The self protection message described HPV symptoms and consequences specific to 
men’s health, including: genital warts, penile and anal cancer. The self- protection and partner 
protection message included the consequences of HPV for men’s health, in addition to the 
potential consequences of HPV for their female partner’s health, including cervical cancer and 
genital warts. All participants, regardless of condition, received other basic information about 
HPV, including HPV prevalence, risk factors, symptoms and diagnosis, treatment and risk 
reduction methods. The self-protective message included the fact that receiptof the vaccine 
would protect men against genital warts and anogenital cancers. The self and partner protective 
message included the same information plus a description of how male receipt of the vaccin  
could indirectly affect their female partner’s health by reducing her risk of genital warts, 
abnormal Pap tests, and cervical cancer (Gerend & Barley, 2009). 
 After viewing the informational passage, participants completed a post test urvey that 
assessed HPV awareness and knowledge, HPV vaccine acceptability and predictors of HPV 
vaccine acceptability. Findings showed that vaccine acceptability was generally high. Correlates 
of vaccine acceptance included higher rates of sexual activity, greater p rc ived susceptibility to 
HPV, greater perceived benefits of the vaccine, higher self-efficacy for vaccination, and greater 
perceived norms for vaccination.  However, vaccine acceptability did not differ as a function of 
26 
 
 
whether the message condition included benefits of vaccination for females. Further, no 
differences emerged by condition when the analysis focused exclusively on men who were in a 
committed relationship at the time (Gerend & Barley, 2009).  
 Following FDA approval of the vaccine for boys and men, DiClemente and colleagues 
(2011) conducted a similar study, presenting college age men with one of three inte v ntion 
messages regarding HPV and the vaccine. The three intervention conditions were classifi d as: 
altruism, personal sexual protection, and personal cancer protection. In the altruism condition, 
participants were presented with basic information about the cause, prevalence and pr vention of 
cervical cancer. The personal sexual protection condition focused on preventing genital warts in 
men and informed participants of their high prevalence and low treatment succes  rates. Lastly, 
in the personal cancer protection condition, the causal link between HPV and head and neck 
cancers was highlighted. A pre-test, post-test design was implemented and results showed that 
male HPV vaccine acceptance increased significantly following receipt of the intervention. 
However, acceptance did not significantly vary by intervention condition received. 
 Several limitations can be identified in both studies. First, while Gerend and Barley 
(2009) conducted their study with reference to hypothetical interest in vaccination, DiClemente 
and colleagues were able to present an FDA approved vaccine to male college stud nts in 
assessing their interest in receiving it. Given the currently low male uptake rates in the U.S. and 
recent ACIP recommendation for boys, further research is needed to provide information 
regarding male acceptance of the now available vaccine. Second, in the Gerend and Barley 
(2009) study, information that male participants received concerning self and part er protection 
was likely insufficient to activate altruistic motives. By only presenting males with a description 
of female consequences of HPV infection, altruistic motives for vaccination may not have been 
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adequately emphasized. Also, by referring only to partner protection, the informati n likely 
appeared to participants as only relevant to protecting their own sexual partners, rather than 
additionally appealing to broader health benefits such as decreasing the preval nc  of cervical 
cancer worldwide. DiClemente and colleagues overcame this limitation by placing greater 
emphasis on the broader health concern of cervical cancer in women. However, a notable 
limitation of the intervention conditions assigned in their study was that the combined effects of 
both broader female health benefits and personal sexual health and cancer protection were not 
tested. While their findings indicated that providing any aspect of information may likely 
increase male motivation to receive the vaccine, there is potential that providing males with all 
aspects of information may enhance acceptance even more. 
The current investigation sought to overcome these limitations and isolate the effect of 
altruism in male HPV vaccination by testing the effects of a brief intervention to promote 
altruistic motives as well as male specific health benefits for vaccin tion among men. Similar to 
DiClemente and colleagues (2011), the intervention stressed the fact that male HPV vaccination 
confers potential protection to the recipient’s sexual partners, as well as broader (population 
level) benefits to women’s health. In particular, males were presented with the concept of herd 
immunity and with an explanation of how individual vaccination can promote community wide 
health benefits by reducing the spread of the disease to others. The intervention also ncluded 
information on the severity and prevalence of female health consequences of HPV and the role 
of men as transmission vectors to females. The connection between male HPV vaccination and 
the elimination of cervical cancer globally was also highlighted.  
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Overview of the Present Study 
Past research on HIV vaccine trial participation (Colfax et al., 2005; Hays & Kegeles, 
1999; Nyamanthi et al., 2007), as well as studies of hypothetical and actual vaccination decisions 
(DiClemente, Crosby, Salazar, Nash & Younge, 2011; Gerend & Barley, 2009; Hershey et al., 
1994), suggest that altruism may help to motivate willingness to vaccinate, particularly in the 
context of a vaccine to prevent an STI.  As a sexually transmitted virus, HPV carries health risks 
for both men and women, although female risks are more prevalent and potentially severe. 
Therefore, providing motivational information about both the personal health benefits of 
vaccination, along with information about partner and societal benefits (stressing altruistic 
motives) may enhance male willingness to pursue vaccination.  
Therefore, the current study addressed this gap in the literature by examining whether a 
brief intervention designed to increase altruistic motivation for vaccination can enhance men’s 
intentions to receive the HPV vaccine. In the previously described studies (DiClemente et al., 
2011; Gerend & Barley, 2009), the message manipulations were very brief and in one, did not 
emphasize the wide-spread health benefits to women and in the other, did not include a 
combination message with both male specific and global female health benefits of vaccination. 
Encouraging altruistic motives in male HPV vaccination may require a more extensive and 
persuasive message that emphasizes the male role in the spread of the disease and consequently, 
the effect that male vaccination can have on widespread reduction of the infection and associated 
health burdens.  
Additionally, informational messaging about HPV related health consequences has 
typically emphasized female health risks (e.g. cervical cancer). In the few studies including 
males, genital warts has been the primary consequence of HPV presented when citing male 
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health risks (Ferris et al., 2009; Jones & Cook, 2008). Given newly emerging evidence for a wide 
variety of male-specific HPV health risks, research is needed to clarify the extent to which 
messages stressing male specific health protection motivates male vaccine cceptance, as 
indicated by the work of DiClemente and colleagues (2011). With the even more recent ACIP 
recommendation of the vaccine for boys and continually advancing findings on the health 
consequences of HPV infection, further investigation on the role of disseminating this 
information to boys and men is critical.  
To address the goal of further informing male HPV vaccine interest and uptake, 
participants in the current study were randomized to receive one of four informational 
interventions that varied in the inclusion or exclusion of altruistic motives and in terms of the 
extent to which male specific HPV-related illnesses and vaccine benefits w re stressed. This 
between subjects design utilized computer administered interventions, in which information was 
presented both visually and with audio voiceover. The informational interventions were 
presented to a college age sample of unvaccinated men. Male college students fall within the 
recommended vaccination age range. Also, increased rates of sexual activity within this age 
group, compared to younger cohorts, make the intervention particularly relevant to this sample, 
given that HPV is a sexually transmitted infection. 
Intervention content for all participants included basic information about HPV and the 
HPV vaccine, including HPV prevalence, modes of transmission and common consequences for 
men and women (genital warts and cervical cancer), as well as facts about the availability nd 
efficacy of the vaccine.  Participants were randomized to one of four conditions including a basic 
condition, an altruism only condition, a male specific HPV-related health consequences only 
condition and an altruism plus male specific HPV-related health consequences condition. It was 
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predicted that participants who received interventions including only altruistic mo ves or only 
male-specific information would endorse greater vaccine acceptance tha those who received 
only basic HPV and HPV vaccine information. Additionally, it was predicted that participants 
who received an intervention message that stressed altruistic motives as w ll s enhanced male-
specific health consequences of HPV and benefits of vaccination would endorse the grea est 
acceptance of the vaccine among all intervention groups. 
Although not central to the primary hypotheses of the study, participants were also 
randomly assigned to either a male or female interventionist voiceover. Prior research indicates 
that group members respond more positively to information communicated by in-group members 
than to the same information provided by out-group members (MacKie, Gastardo-Conaco & 
Skelly, 1992). Therefore, it was predicted that males might be more influenced to onsider the 
vaccine after listening to a male interventionist as compared to a female interventionist. Given 
the overarching goal of understanding factors that encourage male acceptane of the vaccine, 
elucidating any gender effects of message delivery is valuable. 
A secondary aim of the present study was to explore correlates of male willingness to 
receive the HPV vaccine. The current study extends the literature on male HPV vaccine 
acceptance by seeking to replicate the findings of past research indiati g that HPV knowledge, 
perceived HPV susceptibility and severity, and past risky sexual behavior are associated with 
increased vaccine acceptance (e.g., Baer et al., 2002; Crosby et al., 2012; Ferris et al., 2009; 
Gerend & Magloire, 2008; Katz et al., 2011).  Guided by recent findings from a study of African 
American teens (Vanable et al., 2011), exploratory analyses also tested the hypotheses that 
concerns about vaccine safety and stigmatization would be associated with decreased vaccine 
acceptance, and that past exposure to information about Gardasil would be associated with 
31 
 
 
increased vaccine acceptance.  Finally, the present study included a measure of dispositional 
altruism to test the hypothesis that greater dispositional altruism would be associated with 
increased vaccine acceptance, particularly among those who received the interv ntion designed 
to activate altruistic motives. Analyses also sought to clarify whether the influence of 
hypothesized correlates of vaccine acceptance varied as a function of intervention condition.  
Methods 
Participants 
 Male undergraduate participants (N = 200), all over the age of 18, were recruited from the 
introductory psychology course (PSY 205) at Syracuse University. Adequate sample ize was 
determined through a power calculation performed using G*Power 3, a statistical analysis 
software program that is available in the public domain (Faul, Erdfelder, Lang, & Buchner, 
2007). The sample size, using a medium approximate effect size (e.g., f = .25), with an alpha of 
.05 and four experimental conditions, was sufficient to obtain a power level of .90 for the 
primary analysis of variance (ANOVA) analyses.  
 Male undergraduate students enrolled in an introductory psychology course at Syracuse 
University were recruited through Sona-systems, an online human subject pool management 
system. Students first answered a single screener item asking whether ty had ever received the 
HPV vaccine, Gardasil. Participants who answered “no” were deemed eligible for study 
participation. Potential participants viewed a brief description of the study, which described 
participation as involving completion of a series of questionnaires concerning attitudes, 
knowledge, and behaviors related to personal health. Upon completion of the study, participants 
were granted one research credit as part of a class requirement. 
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 The demographic characteristics of the sample are summarized in Table 1. Two hundred 
male undergraduates participated in the study (M age = 19.3, SD = 2.2).  Among whom, 69% 
were Caucasian, 17% were Asian or Pacific Islanders, 11% were African Americans, 4% were 
Latino, and 1% self-identified their ethnicity as “other.”  The majority of participants were 
underclassmen, with the sample consisting of 49% freshmen, 35% sophomores, 9% juniors, and 
8% seniors.  Overall, participants reported a B average (M GPA = 3.1, SD =.64). Eighty-one 
percent reported that they live on campus and 12% play a varsity sport. Fifteen perc t of 
participants reported membership in a social fraternity. When asked to best describe sexual 
orientation, 97% reported being heterosexual, 3% homosexual, and 1% reported being bisexual
or uncertain of sexual orientation.  
Procedure  
Randomization.  Prior to arrival, participants were randomly assigned to one of eight 
study conditions that varied in terms of intervention message content and gender of audio
delivery. Randomization was done using a table of random numbers (1-8) generated by 
GraphPad QuickCalcs, a random number generator available in the public domain (GraphPad 
Software Inc., San Diego, CA). 
Data collection. Data collection occurred during the Fall of 2011. Participants signed up 
for hour-long time slots through SONA. Each study slot allowed for up to 5 participants. 
Throughout the course of data collection, survey administration typically included three or fewer 
participants per session. Participants were provided privacy by completing survey  in different 
rooms or at separate ends of a conference table if in the same room. Noise canceling headphones 
were used to ensure that the audio component of the survey could not be heard by other 
participants. Upon arrival, the principal investigator or trained research assistant distributed 
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consent forms and provided a brief overview of study requirements. Individuals who consented 
were then oriented to the computerized survey instructions.  Participants were ituat d at an 
individual laptop through which they were administered the audio computer assisted survey 
interview (ACASI). They were directed to follow the instructions provided for them on the 
computer and to ask the researcher any questions.  
A series of questionnaires was administered through audio computer- assisted elf 
interviewing (ACASI) which was designed and programmed using MediaLab software (Jarvis, 
2005). Research findings suggest that ACASI methods are equal to or better at eliciting
participant openness in reporting health behaviors than other self-report measures (e.g., Robinson 
& West, 1992; Schroder, Carey, & Vanable, 2003; Turner et al., 1998). Therefore, ACASI was 
chosen for the present study due to its usefulness in encouraging honest disclosure pertaining to 
sexual beliefs and behaviors as well as its utility in maintaining controlled experimental 
conditions among participants.  
 Participants completed the demographics, sexual history and risk behaviors, HPV 
knowledge, the Self Report Altruism Scale, and exposure to Gardasil questionnaires. Following 
these, participants were presented with an audio accompanied PowerPoint presentation 
highlighting the information relevant to their assigned condition. The informational intervention 
messages were balanced for equal length of content and presentation time (see Appendix J). 
Following the informational intervention, participants completed the HPV Vaccin tion 
Acceptance questionnaire assessing their likelihood of receiving the HPV vaccine (Appendix E). 
They also completed the motives for vaccination, perceived HPV susceptibility and severity and 
HPV vaccine attitudes questionnaires. These post-test only measures were chosen to eliminate 
any priming effects that could occur if participants viewed the items prior to intervention. 
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Following completion of the survey, participants were debriefed and thanked for their time. They 
were also provided with a list of resources regarding additional information on HPV and the 
HPV vaccine, including where they can obtain the vaccine, and resources for other questions or 
concerns related to sexual health. 
Measures 
Demographics and background characteristics. Participants completed a 
demographics questionnaire inquiring about age, race/ethnicity, class standing, major, GPA, 
fraternity membership, sexual orientation and relationship status (see Appendix A). 
Sexual history and risk behaviors. Lifetime sexual and risk behaviors were assessed 
using items adapted from a previously developed measure (Vanable et al., 2009). Sexual activity 
status was dichotomized to indicate whether the participant had ever engaged in sexual 
intercourse across their lifetime. For the current study, risky sexual beh vior was assessed using 
summary variables of lifetime and recent (past 3 months) instances of unprtected vaginal or 
anal sex, and lifetime number of sexual partners. The lifetime unprotected sex variable was 
created based on participants’ response to items asking if they had ever engaged i anal or 
vaginal sex without a condom. The recent unprotected sex variable was created based on 
participants’ report of the number of times they had engaged in vaginal or anal sex without a 
condom over the past three months (see Appendix B).  
HPV knowledge. HPV knowledge was assessed using items adapted from previous 
research conducted by Gerend and Barley (2009) and Reiter, Brewer, McRee, Gilb rt and Smith 
(2010). Participants were asked true or false questions that were coded 0 or 1 for correctness 
(e.g. “HPV can cause cancer of the penis or anus in men.”). A composite score was calculated by 
summing the correct number of responses to the ten item questionnaire (see Appendix C). 
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 Self-Report Altruism Scale. The Self Report Altruism Scale (Rushton, Chrisjohn, & 
Fekken, 1981) has been frequently used in research to measure the “altruistic personality” in 
individuals (e.g. Johnson et al., 1989, Phillips, 2008, Takashi, 2012). The scale, which prompts 
participants to rate the frequency with which they have performed 20 altruistic acts (i.e. never, 
once, more than once, often, very often) had high reliability in the present study (α= .85).A 
composite variable was calculated to provide an average score for each participant (See 
Appendix D).  
 Gardasil exposure. Gardasil exposure was measured using 6 dichotomous items 
regarding whether or not one had heard about the HPV vaccine prior to participating in the study 
(e.g., “I have heard about the HPV vaccine from my primary care provider.”) (See Appendix E).  
Composite variables were created by summing the dichotomized responses for three diffe nt 
types of exposure: in person (e.g. from a health care provider), in print (e.g. from a news article 
in a magazine), or in media (e.g. from an ad on TV or radio).  
Perceived HPV susceptibility and severity. Perceived susceptibility to contracting HPV 
was assessed with an eight item measure adapted from previous research (Reiter, Brewer & 
Smith, 2010; Zimet et al., 2005). Items developed by Reiter and colleagues (2010) assessed 
participants’ perceived vulnerability to contracting the following HPV related diseases: genital 
warts, anal, oral and penile cancer. Responses were on a 5-point Likert scale. Reli bility of these 
four items has been found to be .91 (Reiter et al., 2010).  In the present sample, the coeffici nt 
alpha for the full scale was .84. A composite score was calculated by averaging the scores of the 
eight perceived HPV susceptibility items. 
Perceptions of HPV infection severity were assessed with six items that focused on the 
perceived severity of specific HPV-related illnesses.  The measure included three items used in 
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previous research to assess the perceived severity of contracting specific HPV-related health 
conditions (i.e., genital warts, oral cancer and anal cancer; Reiter et al., 2010), as well as three 
new items that assessed the perceived severity of contracting HPV in general ( .g., “How serious 
would it be if you got HPV?”) and the extent to which cervical cancer is perceiv d as severely 
affecting the lives of women (e.g., “ How serious would it be if a female got cervical cancer 
caused by HPV?”).  Severity items were rated using a four point Likert scale, with response 
options ranging from “not at all” to “extremely” (see Appendix F).  A perceived severity 
composite score was calculated by averaging the six item responses. The reliability of the scale 
in the present sample was similar to previous research (Reiter et al., 2010), α= .72. 
HPV vaccine attitudes. An HPV vaccine attitudes scale consisted of 15 items adapted 
from previous research (Vanable et al., 2011). Items assessed concerns about the safety of the 
HPV vaccine (e.g. “I am confident that the HPV vaccine is safe.”), trust in HPV vaccine efficacy 
(e.g. “I trust what is being reported about the HPV vaccine as a way to prevent cervical 
cancer.”), concerns about stigmatization associated with taking the vaccine (e.g., “I would be 
embarrassed if my parents urged me to get the HPV vaccine.”), and general acc ss to vaccination 
concerns (e.g. “I am concerned about the cost of the HPV vaccine.”). The items were measured 
on a 6-point Likert scale ranging from strongly disagree to strongly agree (See Appendix G).  
Principal components analysis with promax rotation was conducted on the scale to 
determine if the described a priori factors emerged. Analyses yielded thre factors that accounted 
for 54% of the variance. Factor 1, which accounted for 30% of the variance, consisted of even 
items that endorsed HPV confidence in vaccine safety and efficacy. The second fact r, which 
accounted for 15% of the variance, was made up of four items assessing concerns regarding 
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stigmatization associated with taking the vaccine. Only one item loaded onto the third factor and 
it was subsequently dropped. 
 Composite scores were calculated for the two factors by averaging scores of the 
associated items. Scales assessing vaccine safety and efficacy (α = .84) and concerns regarding 
vaccine stigmatization (α = .74) had good reliability.    
Motives for vaccination. To ensure that the two distinct intervention messages were 
successful in enhancing (a) male-specific information about the health conseque c s of HPV and 
benefits of vaccination and (b) altruistic motives for vaccination, eight items were developed to 
serve as manipulation checks. Face valid items were constructed asking participants to rate on a 
5-point Likert scale the degree to which they agreed with a series of reasons for seeking 
vaccination (See Appendix H). These questions were administered following participant receipt 
of the informational intervention. Five items specifically sought to assess whether altruistic 
motives for vaccination were activated as a result of viewing the intervention (e.g., “For men, 
getting the HPV vaccine is important because it helps reduce the threat of cervical cancer in 
women.”). A composite score (α = .81) was computed using the average of the responses to the 
five items. Two other items sought to examine the effect of male-specific information (e.g., “It is 
important for men to get the HPV vaccine because it reduces their chance of develping certain 
kinds of oral cancers). The composite for male-specific motives also had strong reliability (r = 
.79).   
 HPV vaccination acceptance. The HPV vaccine acceptance served as the primary 
dependent variable in the present study. Following receipt of the informational intervention 
messages, four items developed and used in previous research inquired about participant’s 
interest in receiving the HPV vaccine (Gerend, Lee & Shepherd, 2007). Items asked participants 
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to rate the likelihood that they would seek out more information about the HPV vaccine, that 
they would consider receiving the HPV vaccine, and that they would actually get the vaccine. A 
fourth item asked participants how likely it is that they will get the vaccine if it is offered to them 
by a healthcare provider within the next year. Three additional items were developed for the 
present study to assess the likelihood that participants would tell male and female riends about 
the HPV vaccine as well as the likelihood that they would ask their doctor about the vaccine t 
their next visit. For each item, participants provided a likelihood rating on a five point Likert 
scale, with response options ranging from ”very unlikely” to “very likely”. A composite score for 
vaccine acceptance was calculated by averaging participants’ responses across the seven items. 
The scale items yielded a high degree of reliability (α = .91) in the current sample. Scale items 
are shown in Appendix I.  
 Principal components analysis with promax rotation was conducted to determine if 
separate constructs emerged within the HPV vaccination acceptance scale. The analysis yielded a 
single factor model that accounted for 64% of the variance. 
Intervention Messages 
All four intervention conditions included essential information about HPV and the HPV 
vaccine based on information provided through the CDC (CDC, 2010). This basic level of 
information (BASIC) included the fact that HPV is the most highly prevalent STI in the U.S. and 
that infections often pass without any symptoms.  Participants were told that genit l warts in both 
men and women are the most common consequence of HPV and that the most serious threat 
posed by HPV is cervical cancer in women. Participants were then informed about the HPV 
vaccine, known as Gardasil, and told that it is FDA approved for both men and women in the 
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U.S.  Participants were told that the vaccine prevents against the four highest r sk strains of HPV 
that cause most cases of cervical cancer and genital warts. 
Intervention message content across the four conditions varied in terms of whether t  
intervention included or excluded information designed to activate altruistic motives for 
vaccination, and in terms of the extent to which male specific HPV-related illn sses and 
vaccination benefits were stressed. In order to achieve this, participants were randomized to one 
of four informational interventions. 
The conditions emphasizing male-specific health conditions related to HPV and benefits 
of vaccination (MALE-INFO) informed participants of medical advancements in the study of 
head and neck cancers associated with HPV in males. A reminder that males are 
disproportionately affected by these types of cancers as compared to females was included in 
addition to prevalence rates. Additionally, the debilitating effects of laryngeal papillomatosis 
were described and its causal link to HPV was noted. Finally, the established association 
between HPV and penile and anal cancers was highlighted. Specification of the strains most 
prevalent in these cancers was provided, especially given that they are those prevented by the 
HPV vaccine. The MALE-INFO intervention included an explanation that the HPV vaccine 
offers protection against the prevalent STI associated with all of the described illnesses, offering 
much promise for improved health prospect. 
The conditions activating altruistic motives in vaccination (ALTRUISM) included female 
specific health risks associated with HPV (primarily cervical cancer), the fact that HPV is easily 
transmitted through sexual activity, and the idea that male vaccination can provide significant 
health benefits for women. The ALTRUISM condition specifically emphasized the tragic health 
burden caused by cervical cancer worldwide. Participants were informed of the prevalenc  and 
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high morbidity of cervical cancer. The direct causal link between HPV infection and cervical 
cancer was highlighted in order to underscore the effect the virus has on the global prevalence 
cancer. ALTRUISM participants were reminded that HPV is easily transmitted through genital 
contact even when symptoms are undetectable and infection is unknown. The condition stressed
the potential health benefits of male vaccination for women and emphasized two related points. 
First, partner specific benefits were noted in that male vaccination can provide direct protection 
for sexual partners. Second, ALTRUISM participants were educated on the conc pt of herd 
immunity and instructed that, ultimately, their vaccination could lead to lower rat s of HPV 
within an entire community. On a global level, lower rates of HPV could lead to decreas d 
worldwide cervical cancer. ALTRUISM participants were motivated through the message that 
their decision to take the vaccine can save female lives in the long run. 
 Initial intervention message content across the four conditions varied in length due to the 
varying inclusion of either MALE INFO, ALTRUISM, both (MALE-INFO + ALTURISM) or 
neither (BASIC). Therefore, filler information on the history of vaccination was added to 
appropriate interventions to achieve comparable delivery time across conditions. Full 
intervention scripts can be found in Appendix J.  
Results 
Descriptive Findings 
 In the complete sample, 81% of participants reported having had vaginal sex in their 
lifetime. On average, participants reported having 4 lifetime sexual partners and 2 sexual 
partners in the past 3 months. Also, 54% of participants had engaged in unprotected vaginal sex 
in their lifetime.  Participants reported an average of five occasions of unprotected sex in the past 
three months.  Participants were only moderately knowledgeable about the causes and 
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consequences of HPV (M  HPV knowledge score = 6.7 out of a possible 10, SD= 1.5). Two-
thirds of the sample (67%) reported that they had ever heard of the HPV vaccine prior to study 
participation, with 52% reporting exposure to TV or radio ads, 42% through print ads such as 
magazine or newspaper articles, and only 22% reported having heard about the vaccine from a 
medical provider. 
 Post intervention, participants across intervention conditions reported moderate interest in 
vaccination (M= 3.2 on a 5 point scale, SD= 1.0), with 43% endorsing that they were very likely 
to seek vaccination, 36% indicating that they were uncertain about whether they would seek 
vaccination, and only 21% reporting that they were unlikely to seek vaccination. 
Primary Data Analyses 
Equivalency across conditions. Prior to testing primary study hypotheses, a series of 
analyses was conducted to confirm the group equivalency among participants randomized to the 
four primary study conditions.  No significant differences emerged between groups on 
categorical variables of: year in college, χ2(9, N = 200) = 0.36, ns, ethnicity, χ2(3, N = 200) = 
0.94, ns, religious affiliation, χ2(3, N = 200) = 0.35, Greek membership, χ2(3, N = 200) = 1.7, ns, 
sexual orientation, χ2(9, N = 200) = 8.4, ns, having ever been in a committed relationship, 
χ
2(3, N = 200) = 4.3, ns, and current relationship status, χ2(3, N = 200) = 4.9, ns. No significant 
differences emerged among continuous variables across groups: age, F(3, 195)= 1.53, ns, GPA, 
F(3, 171)= .59, ns, number of committed relationships, F(3, 146)= 1.11, ns, and lifetime number 
of sexual partners, F(3,196) = .88, ns. 
 Effect of intervention condition on altruistic and male specific vaccination motives. 
The first set of analyses were conducted to test the hypothesis that the experimental 
interventions, created to either provide male-specific HPV information or activate altruistic 
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motives in vaccination, would activate the intended vaccination motives. Results from 
independent samples t tests revealed significant effects for both altruism, t(198) = -3.5, p = 
.001,on the altruistic motives for vaccination measure and for male-specific information, t(198) = 
-5.7, p < .001,  on the male-specific motives for vaccination measure.  Consistent with the 
hypothesis, those who received the intervention that included information designed to activate 
altruistic motives scored higher on the altruistic vaccination motives scale (M = 4.4, SD = .67) 
than did those who did not, (M = 4.1, SD =.74). Likewise, those who received the male-specific 
information messages endorsed male-specific vaccination motives significantly more than those 
who did not receive such intervention content, M = 4.4, SD = .76 vs. M = 3.5, SD = 1.3. Tables 2 
and 3 display mean differences for the motives for vaccination scales as a function of 
intervention condition received.  
 Intervention impact on vaccine acceptance.  To address the primary aim of the study, a 
one-way ANOVA was conducted to identify group differences on HPV vaccine accept nce 
among participants in the four experimental conditions.  It was hypothesized that participants 
who received interventions that included both male specific information and altruistic motives 
would endorse the highest level of vaccine acceptance.  
 The dependent variable, vaccine acceptance, was normally distributed as asses ed by a 
one sample Kolmogorov-Smirnov test (Z= 1.24, p= .09) and visual inspection of histogram and 
p-p plots. There was homogeneity of variance between groups as assessed by Levene's test for 
equality (p > .05), as well as independence of observations as indicated by Durbin Watson 
statistic (d= 2.21).  
 The analysis yielded a significant overall effect, F(3, 196) = 3.54, p = .02 indicating 
significant differences in vaccine acceptance based on type of intervention received. Scheffe’s 
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test elucidated the pattern of group differences. Indeed, among the four groups, the only 
significant difference emerged between the BASIC intervention condition and the MALE-INFO 
+ ALTRUISM intervention condition (p = .02). Those who received the BASIC intervention 
endorsed the lowest interest in the HPV vaccine (M = 3.0, SD = .94). Those who received 
MALE-INFO (M = 3.1, SD = 1.0) and ALTRUISM (M = 3.1, SD = 1.0) endorsed equal interest 
in the vaccine. While participants who received MALE-INFO+ALTRUISM reported the greatest 
HPV vaccine interest (M = 3.6, SD = 1.0). Means and standard deviations for participants in each 
of the four study cells, along with marginal means are shown in Table 4.  In addition, mean 
differences in vaccine acceptance across the four conditions are depicted in Figure 1. The results 
supported the initial prediction that participants receiving both aspects of informati n would be 
the most accepting and interested in the vaccine.   
 Effects of interventionist gender.  Although not central to the primary hypotheses, 
gender of interventionist voice over was examined to determine if vaccine acceptan  among 
males differed by gender of intervention delivery and as a function of intervention condition. An 
independent samples t-test was conducted to examine overall effect of interventionist gender on 
HPV vaccine acceptance among the sample. No significant difference emerged on vaccine 
acceptance among those who received their intervention from a male versus female voiceover, 
t(198)= .03, ns. To determine if interventionist gender had an effect on vaccine acceptance as a 
function of intervention condition, a 4 (intervention condition) x 2 (interventionist gender) 
ANOVA was conducted. Results indicated a marginally significant effect of intervention 
condition, F(3, 192)= 2.57, p = .06, and a non-significant effect of interventionist gender, F(1, 
192)= .03, p = .87. The interaction of condition by gender was also non-significant. 
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Psychosocial Correlates of Vaccine Acceptance 
To clarify the influence of other psychosocial factors on HPV vaccine acceptan  among 
study participants, analyses proceeded in two stages.  First, a series of partial correlations 
between each predictor variable and the dependent variable (HPV vaccination acceptance) was 
conducted, controlling for experimental condition.  Second, significant correlates wer  entered 
into a hierarchical linear regression controlling for intervention condition.  
The proposed predictor variables of HPV knowledge, sexual activity and risk behaviors, 
perceived HPV susceptibility and severity, dispositional altruism, HPV vaccine attitudes, and 
exposure to Gardasil were inspected for assumptions of linearity, independence, 
homoscedasicity, and normality and characterized overall and by intervention group. A summary 
of these variables for each intervention group as well as overall sample can be found in Table 5. 
Of the predictor variables, only perceived HPV susceptibility (r = .23, p = .002) and 
stigmatization concerns toward the HPV vaccine (r = -.15, p = .04) were significantly correlated 
with vaccine acceptance. Partial correlations are found in Table 6.  
Hierarchical linear regression was used to examine the predictive effects of perceived 
HPV susceptibility and stigmatization concerns on vaccine acceptance. Dichotomous indices of 
intervention condition (altruism and male-specific information) were enterd at Step 1, followed 
by the psychosocial variables in Step 2.  As expected, main effects for intervention co dition 
emerged at Step 1, F(2, 197)= 4.54, p = .01, with altruism (β = .15, t(197) = 2.15, p = .03) and 
male-specific information (β = .15, t(197) = 2.11, p = .04) contributing significantly to the 
model. Perceived HPV susceptibility and stigmatization concerns, entered in Step 2, also added 
significantly to the overall model, F(4, 195)= 5.76, p < .001, and accounted for 11% of the 
variance. Both variables were significant predictors of HPV vaccine acc ptance (β =.19, p = .01 
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for perceived susceptibility; β = -.15, p = .03 for stigmatization concerns). Results indicated that 
higher perceived vulnerability to contracting HPV was associated with greater vaccine 
acceptance. Also, lower perceived stigmatization of vaccination was associ ted with greater 
vaccine acceptance.  Including the two predictors resulted in a significant n rease in variance 
explained, F change (2, 195) = 7.39, p = .001. None of the psychosocial variables interacted with 
intervention condition to predict vaccine acceptance.   
Discussion 
 Overall, the major study hypotheses were supported. Findings confirmed that participants 
assigned to the intervention that included both altruistic motives and male-specific information 
reported the highest level of HPV vaccine acceptance across all four intervention conditions. 
Thus, while intervention content stressing either altruistic motives or male specific health 
benefits was observed to enhance interest in vaccination, findings suggest that the additive 
effects of including content from both informational domains maximizes vaccine acceptance.   
This study addresses several limitations of previous research and helps to advance the 
understanding of how to increase male interest and motivation in HPV vaccination. Previous 
research consists primarily of cross-sectional studies that examine correlates of male acceptance.  
The two intervention studies that have been reported (DiClemente et al., 2011; Gerend & Barley, 
2009) did not find significant effects of intervention content on male HPV vaccine accept nce. In 
Gerend and Barley’s (2009) study, the condition that included self and partner protection was 
likely insufficient in activating altruistic motives because it lacked information regarding the 
widespread effects of male vaccination, such as decreased transmission of the virus and 
ultimately, decreased global rates of cervical cancer. A similar study conducted by DiClemente 
and colleagues (2011) compared the impact of an intervention that did frame the benefits of 
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vaccination in terms of altruistic motives (reducing cervical cancer risks); however, the altruism 
intervention was limited in that it did not describe the means through which female health 
protection is spread. Moreover, no participants were exposed to interventions that combined 
information about personal protection and altruistic motives. While the results indicated that 
participants were similarly motivated by each of the three intervention messages, vaccine interest 
did not differ by intervention condition. 
The current study built upon Gerend and Barley (2009) and DiClemente and colleagues’ 
(2011) work by implementing an intervention that promoted altruistic motives for vaccination in 
a concise and comprehensive manner. The current altruistic intervention included g obal 
considerations of cervical cancer as well as a brief description of herd immunity, informing 
participants of the causal mechanism through which women can be protected through male 
vaccination. The current study also included an intervention condition that incorporated both 
altruistic motives and male-specific health benefits in order to address an eential question 
regarding the additive effects of both informational dimensions. 
Additionally, although the described studies (DiClemente et al; Gerend & Barley, 2009) 
presented men with male-specific information about HPV and vaccine benefits, they did not 
include a complete description of the most up to date scientific research. In the intervention 
developed for the present study, participants who received information on male-specific health 
consequences of HPV and benefits of the vaccine were provided with a detailed overview of 
relevant health information as derived from recent medical research. Interventions that included 
male-specific information emphasized the discovered causal link between HPV and penile and 
anal cancers, as well as with head and neck cancers and laryngeal papillomatosis. Further, 
prevalence rates and the fact that men are disproportionately affected by these types of cancers 
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were highlighted. Thus, past research may have been less successful in motivating vaccine 
acceptance through such messages because the interventions only described the more com on 
effects of HPV such as genital warts. Explaining the full spectrum of possible HPV infection 
consequences may be worthwhile in promoting the vaccine to men.   
 A secondary goal of the present study was to examine psychosocial correlates of male 
HPV vaccine acceptance. It was hypothesized that greater HPV knowledge, greater perceived 
HPV susceptibility and severity, and past sexual activity would be associted with greater 
vaccine acceptance. Additionally, higher dispositional altruism, previous exposure t  Gardasil 
information, and decreased safety and stigmatization concerns regarding the vaccine were 
predicted to be associated with greater vaccine acceptance.  Of these, only perceived HPV 
susceptibility and vaccine stigmatization concerns emerged as significant correlates. This is 
somewhat consistent with the literature, as findings on HPV knowledge and sexual activity have 
been mixed (Jones & Cook, 2008; McPartland et al., 2005), while perceived susceptibility to 
HPV infection has reliably been found to be associated with greater vaccine interest (Crosby et 
al., 2011; Gerend & Barley, 2009; Jones & Cook, 2008; Reiter et al., 2010). In the current study, 
greater perceived susceptibility to contracting HPV significantly predict d greater HPV vaccine 
acceptance. Integrating the current findings with previous research, males who perceive 
themselves as vulnerable to HPV seem to consistently show interest in HPV vaccination. 
Therefore, interventions that increase male awareness of the consequences of sexual behaviors, 
namely increased vulnerability to contracting STIs, may serve to increase male uptake of the 
HPV vaccine while also promoting safer sexual behaviors. 
 Vaccine attitudes have more recently emerged as an important aspect in HPV vaccine 
acceptance throughout the literature (Gilbert et al., 2010; Hernandez et al., 2010; Reiter et al., 
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2011; Vanable et al., 2011). In the present study, concerns about stigmatization associated with 
taking the vaccine were associated with decreased vaccine acceptance. Thus, interventions to 
promote vaccination may be most effective if they include messages minimizing stigmatizing 
beliefs about vaccination and normalizing the experience of HPV vaccination as a routine 
measure in personal health. Additional research is also needed to clarify spec ic features of the 
vaccine that men may perceive as stigmatizing.  
Major study strengths include (a) the use of an experimental design to investigate the dual 
effects of two intervention domains on male interest in the HPV vaccine; (b) the implementation 
of concise and comprehensive interventions activating altruistic motives in male HPV 
vaccination; and (c) the incorporation of a thorough overview of male-specific health 
consequences of HPV derived from the most recent medical research.  
Study findings should also be viewed in light of several study limitations. First, the 
present study recruited male participants from a university undergraduate participant pool and 
thus participants were somewhat older than the recommended age range for vaccination. While 
Gardasil is FDA approved for boys and men ages 9 through 26, the vaccine was recently
recommended by the Advisory Committee on Immunization Practices (ACIP) for 11 and 12 year 
old boys. The recommendation also indicated that boys aged 13 through 21 should be given a 
“catch-up” dose of the vaccine if never before vaccinated (CDC, 2011). Second, study findings 
should be replicated with men from underrepresented groups who are at elevated risk for HPV-
related health consequences (e.g. men who have sex with men, individuals who have weakened 
immune systems including HIV/AIDS infected persons). In the current study, nearly three-
fourths of the sample self- identified as Caucasian. Thus, findings should be replicated in 
community settings with a more economically and ethnically diverse sample. Finally, the current 
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study utilized self-report measures of HPV vaccine acceptance ratherthan behavioral measures 
of vaccine uptake. Future investigations should implement experimental designs that provide 
access to both vaccine acceptance measures and actual vaccine uptake. Subsequently, an 
important direction for future research would be to test the independent and combined effects of 
male specific information and altruistic motives in pediatric health care settings that serve 
diverse patient populations.  
 The HPV vaccine holds great promise for decreasing the prevalence of the world’s most 
common STI and protecting women from developing cervical cancer. Findings from the present 
study suggest that brief interventions that provide information about male specific b nefits of 
vaccination, as well as the benefits to women and society at large may be effective in motivating 
the decision to vaccinate. Given the very low rates of male vaccination currently observed in the 
United States and the potential value of vaccination in reducing both male and female h alth 
problems, it is important that research and practice move efficiently towards implementing 
effective interventions to increase vaccine uptake among boys.   
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Table 1. Demographic Characteristics 
Characteristic (N =  200) % M SD 
Age  19.3 2.2 
 
Ethnicity 
   Caucasian 
   African American 
   Asian 
   Latino 
   Other 
 
 
 
69 
11 
17 
4 
1 
  
 
Year in school 
   Freshman 
   Sophomore 
   Junior 
   Senior 
 
 
49 
35 
9 
8 
 
  
Living Situation 
   Dorm 
   On-campus apartment 
   Off-campus apartment 
   Fraternity house 
   Parents’ house 
 
65 
16 
15 
3 
2 
  
 
GPA 
  
3.10 
 
.64 
 
Social Fraternity Membership 
 
15 
  
 
Varsity athlete 
 
12 
  
 
Religious Affiliation 
 
45 
  
 
Sexual Orientation 
   Heterosexual 
   Homosexual 
   Bisexual 
   Uncertain 
 
 
97 
3 
.5 
.5 
  
 
Ever being in a Committed 
Relationship 
 
 
75 
 
 
 
 
Number of committed relationships 
  
2.49 
 
1.6 
 
Current Romantic Relationship Status 
    Single 
    Dating 
 
 
67 
34 
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Table 2. Altruistic Motives for Vaccination Means (Standard Deviations) Between Groups  
 Altruism 
 
Motives for Vaccination Yes (n=100) No (n=100) 
Altruistic Vaccination 
Motives 
 
4.4 (.67) 4.1 (.74) 
Male-specific 
Vaccination Motives 
 
3.9 (1.3) 4.0 (1.0) 
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Table 3. Male-specific Motives for Vaccination Means (Standard Deviations) Between Groups 
 Male- specific Information 
Motives for Vaccination Yes (n= 100) No (n= 100) 
Altruistic Vaccination 
Motives 
 
4.2 (.76) 
 
4.2 (.69) 
 
Male-specific 
Vaccination Motives 
 
4.4 (.76) 3.5 (1.3) 
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Table 4. HPV Vaccine Acceptance Means (Standard Deviations) by Intervention Condition 
 Altruism  
 No 
 
Yes 
 
Marginal 
 
Male- specific 
Information 
No  
 
3.0 (.94) 
(n=50) 
 
3.1 (1.0) 
(n=50) 
3.1 (.97) 
Yes 
 
3.1 (1.0) 
(n=50) 
 
3.6 (1.0) 
(n=50) 
3.4 (1.1) 
 Marginal 3.1 (1.0) 3.4 (1.1) 3.2 (1.0) 
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Table 5. Descriptive Data for Predictor Variables by Condition and Overall 
Variable (Scale) Basic  
(n = 50) 
Male-Info 
(n = 50) 
Altruism 
(n = 50) 
Male-Info + 
Altruism 
(n =50)  
p 
Total 
Sample 
(N = 200) 
HPV Knowledge 
(1-10) 
 
6.7 (1.3) 6.4 (1.4) 6.9 (1.7) 6.5 (1.3) ns 6.6 (1.5) 
Sexually Active 
(%) 
 
76 76 90 80 ns 81 
Lifetime 
Unprotected Sex 
(0-2) 
 
.70 (.70) .62 (.70) .80 (.64) .62 (.70) ns .70 (.68) 
Recent Unprotected 
Sex 
 
4.1 (12.1) 5.3 (12.8) 5.4 (11.4) 6.4 (13.7) ns 5.3 (12.5) 
Lifetime Number 
Sexual Partners 
 
3.7 (5.0) 4.0 (4.9) 5.6 (11.5) 4.9 (8.3) ns 4.5 (7.9) 
Dispositional 
Altruism (1-5) 
 
2.5 (.5) 2.6 (.5) 2.7 (.5) 2.6 (.5) ns 2.6 (.5) 
Gardasil Exposure 
In person (%) 
 
16 20 26 24 ns 22 
Gardasil Exposure 
Print (%) 
 
40 42 44 40 ns 42 
Gardasil Exposure 
Media (%) 
 
64 52 52 48 ns 54 
Perceived HPV 
Susceptibility (1-5) 
 
2.4 (.5) 2.4 (.6) 2.3 (.6) 2.5 (.6) ns 2.4 (.6) 
Perceived HPV 
Severity (1-4) 
 
3.7 (.4) 3.6 (.4) 3.7 (.4) 3.8 (.3) ns 3.7 (.4) 
HPVV Attitudes: 
Safety & Efficacy 
Concern (1-6) 
 
3.2 (1.0) 3.3 (.8) 3.2 (.9) 3.2 (.9) ns 3.2 (.9) 
HPVV Attitudes: 
Stigmatization 
Concern (1-6) 
 
2.4 (.1.0) 2.4 (.9) 2.2 (.8) 2.4 (1.0) ns 2.4 (.5) 
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Table 6. Partial Correlations of Predictor Variables with HPV Vaccine Acceptance 
Variable 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. HPV Vaccine Acceptance --              
2. HPV Knowledge -.02 --             
3. Sexual Activity Status .03 .06 --            
4. Lifetime Unprotected Sex .02 .19** .49** --           
5. Recent Unprotected Sex -.04 .15** .22** .48** --          
6. Lifetime Number Sexual Partners .05 .04 .27** .45** .43** --         
7. Perceived HPV Susceptibility .22** -.02 .04 .09 .07 .10 --        
8. Perceived HPV Severity .11 .01 .14* .07 .03 -.01 .07 --       
9. Dispositional Altruism .07 .08 .05 .07 .04 .05 -.04 -.05 --      
10. HPVV Attitudes Safety & Efficacy -.08 -.04 .04 -.08 <.001 -.01 -.08 -.15* .07 --     
11. HPVV Attitudes Stigmatization -.15* -.19**  .02 .07 -.003 .03 -.12 -.10 .07 .30** --    
12. Gardasil Exposure In Person -.01 .08 .09 .08 .09 .02 .09 .03 .17* -.16* -.10 --.   
13. Gardasil Exposure Print .10 .12 .03 .08 .11 .10 .03 .04 .16* .01 -.001 .26** --  
14. Gardasil Exposure Media -.02 .12 .08 .05 -.01 -.03 -.03 .14* .08 -.01 -.03 .27** .59** -- 
*p< .05 
**p < .01 
Note. HPV Vaccine Acceptance & Intent measured on 5-point Likert scale (1= Very unlikely, 5= Very likely); HPV Knowledge: total of correct responses to 10 questions; 
Sexual Activity Status: 0= No, 1= Yes; Lifetime Unprotected Sex:0= Never, 1= vaginal or anal sex without a condom ever, 2= vaginal and anal sex without a condom 
ever; Recent Unprotected Sex: number of occurrences of vaginal and anal sex without a condom in past 3 months; Perceived HPV susceptibility measured on a 5-point 
Likert scale (1= Almost no chance, 5= Almost certain chance; Perceived HPV severity measured on a 4-point Likert scale (1= Not at all, 4= Extremely); Dispositional 
Altruism measured on 5-point scale (1= Never, 5= Very often); HPVV Attitudes Concerns & Stigma measured on 6-point Likert scale (1=Strong Disagree, 6= Strongly 
Agree); Gardasil Exposure in Person single dichotomized item (0= No, 1= Yes); Gardasil Exposure Print: sum of 2 dichotomized (0= No, 1= Yes) items; Gardasil 
Exposure Media: sum of 3 dichotomized (0= No, 1= Yes) items. 
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Table 7. Hierarchical Regression Analyses 
 HPV Vaccine Acceptance & Intent 
 
 Predictor R²              ∆R²              F Change β p 
 
Step 1 
 
 
 
Male-Info 
Altruism 
 
.04 .04 4.5  
 
.15 
.15 
.01 
 
.04 
.03 
Step 2 
 
 
 
HPV 
Susceptibility 
HPVV Attitudes 
Stigmatization 
.13 .08 6.6  
 
.19 
-.15 
< .001 
 
.01 
.03 
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Figure 1. HPV vaccine acceptance means by intervention condition. Standard errors are 
represented by error bars attached to each column. 
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Appendix A 
 
Demographics & Background Characteristics 
 
Demographics 
1.  What is your gender? 
□ Male □   Female 
  1     2   
 
2.  What is your age?   ________  
 
 
3.  What is your ethnic background? 
□ 1 African American  □  3 Latino  □  5 Asian/Pacific Islander 
□ 2 White/Caucasian  □  4 Native American □  6 Other: 
________________ 
 
 
4.  What year are you at SU? 
□ 1 Freshman  □ 2 Sophomore        □ 3 Junior    □ 4 Senior   
 
 
5.  What is your current GPA?  _______ 
 
 
6.  What is your major? _______________________________ 
 
 
7.  Do you belong to a social sorority or fraternity? 
No  Yes 
 0    1 
 
8.  Where do you live?  
□ 1 Dorm  □ 3 On-campus apartment □  5 Off-campus apartment/house 
□ 2 Parents’ Home □ 4 Sorority/Fraternity house □  6 Other:_________________ 
 
9.  Do you play a varsity sport at SU? 
 
No  Yes 
 0    1 
           
 
 
 
60 
 
 
10.  Do you have a religious affiliation? 
No  Yes 
□ 0  □ 1   
 
10a. What is your religious affiliation? _____________________ 
 
11. How many sisters do you have? ______ 
 
12. How many brothers do you have? _______ 
 
11.  Which of the following statements applies best to you? 
1□ I self -identify as heterosexual (attracted to women only). 
2□ I self- identify as homosexual (attracted to men only). 
3□ I self- identify as bisexual (attracted to men and women). 
4□ I am uncertain of my sexual identity.         
 
12. Have you ever been in a committed romantic relationship? 
No Yes 
 
13. If ‘Yes’, how many? 
 
14. What is your current romantic relationship status? 
(1) single, not interested in dating 
(2) single, interested in dating  
(3) dating casually  
(4) dating one person, but not exclusively  
(5) in a committed romantic relationship 
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Appendix B 
 
Sexual History & Behaviors 
 
Lifetime Sexual Behaviors 
 
Directions: This section will ask you about your relationship and sexual history.  Please check 
Yes for any of the following behaviors that you have ever engaged in and check No for those that 
you have never engaged in. 
     
Have you ever, IN YOUR LIFE…  
 
 NO (0) YES (1) 
1. Had vaginal sex WITHOUT a condom?   
2. Had vaginal sex WITH a condom?   
3. Given oral sex WITHOUT a condom?   
4. Given oral sex WITH a condom?   
5. Received oral sex WITHOUT a condom?   
6. Received oral sex WITH a condom?   
7. Had anal sex WITHOUT a condom?   
8. Had anal sex WITH a condom?   
9. Have you been tested for an STD or HIV?   
10. Have you been diagnosed with an STD or HIV?   
            
                    
 
 
 
 
 
 
 
 
 
 
 
11.  How many men have you had sexual intercourse with in your life?     #_____ men      
 
 
12.  How many women have you had sexual intercourse with in your life?   #_____women     
 
 
13.  At about what age did you first have sexual intercourse (vaginal or anal sex)?   ____ years 
old    
                    □ I’ve never had sex. 
               
                                                                           
10a.  IF YES, check all that apply:  
                                       
 
  Chlamydia  
         1 
HPV (genital warts) 
 2  
 Gonorrhea 
 3 
 Genital herpes 
 4 
 Syphilis 
 5  
 Hepatitis A 
 6 
  Hepatitis B 
 7 
 Hepatitis C 
8 
         Trichomonas   HIV                 other: please specify  _______________ 
       9                                     10                                               11 
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Sexual Behavior, Last Three Months  
 
Directions: This section concerns experiences you might have had in the last three months.  
Please indicate, to the best of your ability, how many times you have engaged in each behavior 
in the last three months.  If you have not engaged in the behavior during the last three months,
please write 0 rather than leaving the question blank. 
 
 
Please estimate, over the last three months, how often you engaged each of the ollowing 
behaviors: 
 
In the past three months, how many times have you…. 
 
14.  Had vaginal sex WITHOUT a condom? _____ Times 
 
15.  Had vaginal sex WITH a condom? _____ Times  
 
16. Received oral sex WITHOUT a condom? _____ Times  
    
17. Received oral sex WITH a condom? _____ Times  
       
18.  Given oral sex WITHOUT a condom? _____ Times 
 
19.  Given oral sex WITH a condom? _____ Times 
 
20.  Had anal sex WITHOUT a condom? _____ Times 
 
21.  Had anal sex WITH a condom? _____ Times  
 
22.  Been tested for an STD or HIV? _____ Times  
 
23.  Been diagnosed with an STD or HIV? _____ Times  
 
24.  How many female sexual partners have you had in the last three months? 
                                             
         #______   
                                        
 
25.  How many male sexual partners have you had in the last three months? 
                                             
              #______   
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Appendix C 
 
HPV Knowledge  
 
Directions: The following includes a series of statements regarding human papillomavirus 
(HPV). Please indicate whether you believe the statement is True or False based on your current 
knowledge. 
 
 True (1) False (0) 
1. HPV causes health problems for males.   
2. You can get HPV from having sex.   
3. HPV can cause genital herpes.   
4. HPV infection is rare.   
5. HPV can cause genital warts.   
6. HPV can cause oral cancer.   
7. Most people with genital HPV have no visible signs or 
symptoms. 
  
8. HPV can cause anal cancer.   
9. People can transmit HPV to their partner(s) even if they have no 
symptoms of HPV. 
  
10. Having multiple sexual partners increases a person’s risk of 
getting HPV. 
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Appendix D 
 
The Self Report Altruism Scale 
Directions: Check the category on the right that conforms to the frequency with which you have 
carried out the following acts. 
 Never 
1 
Once 
2 
More than 
once 
3 
Often 
4 
Very 
often 
5 
1. I have helped push a stranger’s car out of the 
snow. 
     
2. I have given directions to a stranger.         
3. I have made change for a stranger.      
4. I have given money to a charity.      
5. I have given money to a stranger who needed it 
(or asked me for it). 
     
6. I have donated goods or clothes to a charity.      
7. I have done volunteer work for a charity.      
8. I have donated blood.      
9. I have helped carry a stranger’s belongings 
(books, parcels, etc.). 
     
10. I have delayed an elevator and held the door 
open for a stranger. 
     
11. I have allowed someone to go ahead of me in a 
lineup (at photocopy machine, in the 
supermarket). 
     
12. I have given a stranger a lift in my car.      
13. I have pointed out a clerk’s error (in a bank, at 
the supermarket) in undercharging me for an 
item. 
     
14. I have let a neighbor whom I didn’t know too 
well borrow an item of some value to me (e.g., a 
dish, tools, etc.) 
     
15. I have bought ‘charity” Christmas cards 
deliberately because I knew it was a good cause. 
     
16. I have helped a classmate who I did not know 
that well with a homework assignment when my 
knowledge was greater than his or hers. 
     
17. I have before being asked, voluntarily looked 
after a neighbor’s pet without being paid for it. 
     
18. I have offered to help a handicapped or elderly 
stranger across a street. 
     
19. I have offered my seat on a bus or train to a 
stranger who was standing. 
     
20. I have helped an acquaintance to move 
households. 
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Appendix E 
 
Gardasil Exposure 
Directions: “Now, some information about HPV and a new vaccine that is available to prevent 
HPV. As you may know, HPV is a common sexually transmitted infection that can lead to a 
variety a health concerns including genital warts in both men and women and cervical cancer in 
women. An HPV vaccine is now available that protects against most genital warts and cervical 
cancer. The HPV vaccine is often referred to by its brand name, Gardasil.”  
 
1.  How much do you know about Human Papillomavirus, often referred to as HPV? 
Never heard of it before (1)    Very little (2)  Some (3)  A lot (4) 
 
2.  Before today, have you ever heard of the HPV vaccine or Gardasil? . 
 No (0)  Yes (1) 
 
3.  To the best of you knowledge, has the HPV vaccine, Gardasil, been approved for use in men?  
 
 No (0)  Yes (1) Not sure (0) 
 
4. Have you heard about the HPV vaccine, Gardasil, from an ad on TV or the radio?  
 No (0)  Yes (1) 
 
5. Have you heard about the HPV vaccine, Gardasil, from a health care provider?  
 No (0)  Yes (1) 
 
6. Have you heard about the HPV vaccine, Gardasil, from a written news article in a magazine or 
newspaper?  
 No (0)  Yes (1) 
 
7. Have you heard about the HPV vaccine, Gardasil, from a TV news program or talk show? 
 No (0)  Yes (1) 
 
8. Have you heard about the HPV vaccine, Gardasil, from a radio news program or talk show? 
 No (0)  Yes (1) 
 
9. Have you read about the HPV vaccine, Gardasil, from an internet website? 
 No (0)  Yes (1) 
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Appendix F 
 
Perceived HPV Susceptibility & Severity 
 
Perceived HPV Susceptibility 
Directions: The following includes a series of questions regarding the effect of STDsand HPV. Please 
indicate the likelihood that you believe each might happen. 
 
 
 Almost no 
chance 
(1) 
Low 
chance 
(2) 
Moderate 
chance 
(3) 
High 
chance 
(4) 
Almost 
certain 
chance (5) 
1. What is the chance that you will 
get a sexually transmitted disease 
in the next 5 years?  
     
2. What is the chance that most 
people in your community will get 
at least one STD in their lifetime? 
     
3. Without the HPV vaccine, what is 
the chance that you will contract 
Human Papillomavirus (HPV) in 
the next 5 years?  
     
4. Without the HPV vaccine, what is 
the chance that most people in your 
community will contract Human 
Papillomavirus (HPV) in their 
lifetime? 
     
5. Without the HPV vaccine, what 
do you think is the chance that you 
will get genital warts in the future? 
     
6. Without the HPV vaccine, what 
do you think is the chance that you 
will get anal cancer in the future? 
     
7. Without the HPV vaccine, what 
do you think is the chance that you 
will get oral cancer in the future? 
     
8. Without the HPV vaccine, what 
do you think is the chance that you 
will get penile cancer in the future? 
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Perceived Severity of HPV 
 
Directions: The following includes a series of questions regarding the effect of STDs. Please indicate 
how much your life might be impacted. 
 
 Not at 
all (1) 
A little 
(2) 
Moderately 
(3) 
Extremely 
(4) 
1. How much do you think having genital warts 
would affect your life?   
    
2. How much do you think having oral cancer 
would affect your life? 
    
3. How much do you think having anal cancer 
would affect your life? 
    
4. How serious would it be if you got HPV?     
5. How serious would it be if you got oral cancer 
caused by HPV? 
    
6. How serious would it be if a female got 
cervical cancer caused by HPV? 
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Appendix G 
 
HPV Vaccine Attitudes  
Directions: Please indicate to what extent you agree or disagree with the following statements 
about the HPV vaccine. 
 
Strongly Disagree Disagree Slightly Disagree Slightly Agree Agree Strongly Agree 
 
 1 2 3 4 5 6 
1) I would hesitate to get the HPV vaccine because 
I’ve heard that the vaccine may not be safe. 
      
2) I am concerned about potential side effects of 
the HPV vaccine. 
      
3) Concern about side effects would prevent me 
from getting the HPV vaccine. 
      
4) There are dangers that we don’t know about in 
taking the HPV vaccine. 
      
5) I am confident that the HPV vaccine is safe.         
6) The HPV vaccine is being pushed to make 
money for drug companies.   
      
7) I trust what is being reported about the HPV 
vaccine as a way to prevent cervical cancer. 
      
8) I don’t trust the information I’ve heard about the 
HPV vaccine. 
      
9) I would not talk to my doctor or healthcare 
provider about the HPV vaccine because he or she 
might think poorly of me. 
      
10) I would be embarrassed if my parent(s) urged 
me to get the HPV vaccine.   
      
11) Receiving the HPV vaccine would be 
embarrassing for me because it is a vaccine to 
prevent a sexually transmitted disease. 
      
12) I don't have enough information about the 
HPV vaccine to decide whether it’s a good idea. 
      
13) I am concerned that getting the HPV vaccine 
would be stigmatizing. 
     
14) I am concerned about the cost of the HPV 
vaccine. 
      
15) If I got the HPV vaccine, I might use condoms 
less often. 
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Appendix H 
 
Motives for HPV Vaccination 
Directions: Based on what you just learned, please indicate how much you agree or disagree 
with each of the following statements. 
 
 Extremely 
disagree 
(1) 
Somewhat 
disagree 
(2) 
Neither 
agree nor 
disagree (3) 
Somewhat 
agree (4) 
Extremely 
agree (5) 
1. For men, getting the HPV 
vaccine is important because it 
helps reduce the threat of cervical 
cancer in women. 
     
2. For men, getting the HPV 
vaccine is important because it 
reduces women’s risk of contracting 
HPV.  
     
3. For men, getting the HPV 
vaccine is important because it will 
help spread immunity to HPV 
throughout communities and 
globally. 
     
4. For men, an important reason to 
get the HPV vaccine is that it will 
prevent the spread of HPV to sexual 
partners. 
     
5. It is important for men to get the 
HPV vaccine because the more 
people vaccinated, the less women 
will suffer from cervical cancer 
worldwide. 
     
6. It is important for men to get the 
HPV vaccine because it reduces 
their chance of contracting penile 
and anal cancers. 
     
7. For men, it is important to get the 
HPV vaccine because it decreases 
their likelihood of contracting HPV 
which could lead to genital warts. 
     
8. It is important for men to get the 
HPV vaccine because it reduces 
their chance of developing certain 
kinds of oral cancers. 
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Appendix I 
 
HPV Vaccination Acceptance  
Directions: The following asks about the HPV vaccine. Please indicate the likelihood of each of the 
following. Based on what you just learned… 
 
How likely is it that you will…  
 Very 
Unlikely (1) 
Somewhat 
unlikely (2) 
Neither 
unlikely nor 
likely  (3) 
Somewhat 
likely (4) 
Very likely 
(5) 
1.  try to get more information 
about the HPV vaccine? 
 
     
2. tell your male friends and 
family about this vaccine. 
 
     
3. tell your female friends and 
family about this vaccine. 
 
     
4. ask your doctor about this 
vaccine at your next visit. 
 
     
5. consider getting the HPV 
vaccine? 
 
     
6. actually get the HPV 
vaccine? 
 
     
7. get the HPV vaccine if a 
health care provider offers it to 
you within the next year? 
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Appendix J 
 
Intervention Message Scripts 
 
Minimal male specific content & No Altruism (BASIC) 
“Human papillomavirus, or HPV, is the most common sexually transmitted disease in the 
World. It affects both men and women and about one out of every two people will contract HPV 
in their lifetime. Very often, people do not know that they have HPV, since there are frequ ntly 
no signs or symptoms. Also, transmission doesn’t even require intercourse, only skin to skin 
genital contact. Therefore, even condoms cannot fully protect you against HPV. Because of this, 
men and women can get HPV very easily and pass it on without even realizing it. The most 
common consequences of HPV are genital warts in both men and women and cervical cancer in 
women.  
Fortunately, there is a new vaccine available to prevent HPV in both men and women. 
Gardasil was FDA approved in 2006 for girls and women ages 9 through 26, and approved for 
boys and men in 2009. Gardasil is a vaccine that prevents four strains of HPV, two that cause 
70% of cervical cancer cases and two that cause 90% of genital warts. The vaccin is overed by 
some, but not all insurance companies. The HPV vaccine has been found to be safe and effective 
in large scale clinical trials. 
Vaccination for a variety of health conditions has a long history both worldwide and in 
the United States.  The history of vaccination dates back to the eighteenth century. A physician 
named Edward Jenner noticed that milkmaids in his town did not generally get smallpox,  
common disease. He hypothesized that the pus in blisters, which milkmaids got from cowpox (a 
disease similar to smallpox), protected the milkmaids from getting smallpox because of the 
protective agents provided. He tested his hypothesis by taking pus from a cowpox lesion and 
injecting it into an eight year old boy. The boy was then exposed to smallpox multiple times and 
found unaffected by it. Jenner’s experimentation and publications truly laid the groundw rk for 
vaccinations to come. 
A major player in the field following the accomplishments of Jenner, was Louis Pasteur. 
Pasteur adopted and applied the word vaccine to his work and defined it as “a suspension of live 
or inactivated microorganisms or fractions thereof administered to induce immunity and prevent 
infectious disease.” He proceeded to produce the first rabies vaccine by growing the virus in 
rabbits, and then weakened the virus by drying the affected nerve tissue. Vaccination for anthrax 
affecting livestock was also studied and developed by Pasteur. 
The early framework laid by Jenner and Pasteur resulted in a medical and cultural shift in 
public health. In the United States, vaccination has become a customary part of societal
expectations. Children are recommended to receive immunizations for Diphtheria, Tetanus, 
Pertussis, Hepatitis B, Pneumonia, Polio, Measles, Mumps and Rubella, Varicella, and Hepatitis 
A all before the age of six. For those 7 to 18 years old, HPV, Meningitis, and yearly Influenza 
vaccinations are recommended.” 
 
 
 
 
 
 
72 
 
 
Enhanced male specific content & No Altruism (MALE-INFO) 
“Human papillomavirus, or HPV, is the most common sexually transmitted disease in the 
World. It affects both men and women and about one out of every two people will contract HPV 
in their lifetime. Very often, people do not know that they have HPV, since there are frequ ntly 
no signs or symptoms. Also, transmission doesn’t even require intercourse, only skin to skin 
genital contact. Therefore, even condoms cannot fully protect you against HPV. Because of this, 
men and women can get HPV very easily and pass it on without even realizing it. The most 
common consequences of HPV are genital warts in both men and women and cervical cancer in 
women.  
Fortunately, there is a new vaccine available to prevent HPV in both men and women. 
Gardasil was FDA approved in 2006 for girls and women and in 2009 for boys and men. 
Gardasil is a vaccine that prevents four strains of HPV, two that cause 70% of cervical cancer 
cases and two that cause 90% of genital warts. The vaccine has been found to be safe and 
effective in large scale clinical trials. 
 Even though HPV is most thought about in terms of female cervical cancer risk, it is 
important for you to know that HPV is linked to serious health consequences for men too. For 
example, HPV causes some types of penile and anal cancers. Recent research indicates that HPV 
may cause over 50% of penile cancer cases and over 90% of anal cancer cases among men. 
Fortunately the strains of HPV linked to these male cancers are prevented by the HPV vaccine. 
There are several other health risks for men associated with HPV and thus protected by 
the vaccine, Gardasil. Recent medical research has found a strong association between HPV and 
head and neck cancers in men. In fact, men are most affected by these HPV -related cancers 
compared to women and approximately 5,700 men are diagnosed with these cancers each year in 
the U.S. Research shows that HPV infection can lead to a 6 fold increase in risk for oral cancer, a 
type of head and neck cancer. Laryngeal papillomatosis is also caused by HPV infection. It can 
lead to warts in the throat and respiratory areas that cause difficulty breathing nd swallowing. 
This condition happens four times more in men than it does in women. Fortunately, if taken prior 
to HPV infection, the HPV vaccine can greatly reduce the chances of these typ of cancers. 
To reiterate, the HPV vaccine, Gardasil, is currently available for boys and men who fall 
within the recommended age range of 9 to 26 years old. It is covered by some, but not all 
insurance companies. Getting the vaccine does not just protect you from HPV but holds great 
promise for preventing a number of serious male health consequences that are caused by HPV.” 
“Vaccination, for a variety of health conditions, has a long history both worldwide and in 
the United States. The history of vaccines dates back to the eighteenth century. A physician 
named Edward Jenner hypothesized that cowpox pus in blisters on the hands of milkmaids, 
(cowpox being a disease similar to smallpox), protected the milkmaids from getting smallpox. 
He tested his hypothesis by taking pus from a cowpox lesion and injecting it into a young boy 
and exposing him to smallpox. Jenner’s hypothesis was correct and his experimentation and 
publications truly laid the groundwork for vaccinations to come. Later on, Louis Pasteur dopted 
and applied the word vaccine from Jenner’s work. He proceeded to produce the first rabies 
vaccine by growing the virus in rabbits, and then weakened the virus by drying the affect d 
nerve tissue. Vaccination for anthrax affecting livestock was also studied and developed by 
Pasteur. In the history of vaccination these two men truly paved the way.” 
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Minimal male specific content & Altruism (ALTRUISM)  
 “Human papillomavirus, or HPV, is the most common sexually transmitted disease in 
the World. It affects both men and women and about one out of every two people will contract 
HPV in their lifetime. Very often, people do not know that they have HPV, since there ar  
frequently no signs or symptoms. Also, transmission doesn’t even require intercours , only skin 
to skin genital contact. Therefore, even condoms cannot fully protect you against HPV. Because 
of this, men and women can get HPV very easily and pass it on without even realizing it. The 
most common consequences of HPV are genital warts in both men and women and cervical 
cancer in women.  
Fortunately, there is a new vaccine available to prevent HPV in both men and women. 
Gardasil was FDA approved in 2006 for girls and women and in 2009 for boys and men. 
Gardasil is a vaccine that prevents four strains of HPV, two that cause 70% of cervical cancer 
cases and two that cause 90% of genital warts. The vaccine has been found to be safe and 
effective in large scale clinical trials.  
By far the greatest health burden of HPV is cervical cancer in women. HPV contributes 
to approximately 12,000 new cervical cancer cases and 4,000 cervical cancer deaths in the 
United States and 275,000 cervical cancer deaths worldwide. In fact, cervical can er is the 
second most common cancer in women in the world. In the U.S., cervical cancer is often 
prevented because of widespread and affordable screening programs that detect HPV infection in 
women. However, this screening is not available in most parts of the world. Over 85% of 
cervical cancer deaths are in developing countries where cervical cancerus s the greatest 
number of female deaths due to cancer. Keep in mind that HPV is sexually transmitted and easily 
passed from partner to partner. Male infection can easily spread to female partners which can 
result in serious female health consequences. 
 The HPV vaccine is currently available for boys and men who fall within the 
recommended age range of 9 to 26 years old. It is covered by some, but not all insurance 
companies. This vaccine is exciting because it prevents the types of HPV that cause cervical 
cancer in women. Knowing this is not only important for women, but it is important for men too. 
Because the HPV vaccine offers something referred to as “Herd Immunity,” you, as a man, can 
play a significant role in reducing women’s risk for cervical cancer. 
 Herd immunity is a concept that explains vaccinations and when they work best. 
Basically, an entire community acquires greater immunity to infection if more and more people 
get vaccinated.  As the number of people receiving the vaccine increases, few r people spread 
the infection and therefore the rate of infection decreases overall. This concept is important for 
men considering the HPV vaccine, because if you and other men get vaccinated, immunity will 
spread faster and women will have better protection from getting cervical cancer. Ultimately, by 
taking the HPV vaccine, men like you can contribute to decreasing community and worldwide 
HPV rates, thus reducing cervical cancer worldwide. Consider how your HPV vaccination can 
help to save female lives in the long run.” 
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Enhanced male specific content & Altruism  (MALE INFO + ALTRUISM)  
 “Human papillomavirus, or HPV, is the most common sexually transmitted disease in 
the World. It affects both men and women and about one out of every two people will contract 
HPV in their lifetime. Very often, people do not know that they have HPV, since there ar  
frequently no signs or symptoms. Also, transmission doesn’t even require intercours , only skin 
to skin genital contact. Therefore, even condoms cannot fully protect you against HPV. Because 
of this, men and women can get HPV very easily and pass it on without even realizing it. The 
most common consequences of HPV are genital warts in both men and women and cervical 
cancer in women.  
Fortunately, there is a new vaccine available to prevent HPV in both men and women. 
Gardasil was FDA approved in 2006 for girls and women and in 2009 for boys and men. 
Gardasil is a vaccine that prevents four strains of HPV, two that cause 70% of cervical cancer 
cases and two that cause 90% of genital warts. The vaccine has been found to be safe and 
effective in large scale clinical trials.  
 Even though HPV is most thought about in terms of female cervical cancer risk, it is 
important for you to know that HPV is linked to serious health consequences for men too. For 
example, HPV causes some types of penile and anal cancers. Recent research indicates that HPV 
may cause over 50% of penile cancer cases and over 90% of anal cancer cases among men. 
Fortunately the HPV types that are linked to these male cancers are prevented by the HPV 
vaccine. 
There are several other health risks for men associated with HPV and thus protected by 
the vaccine, Gardasil. Recent medical research has found a strong association between HPV and 
head and neck cancers in men. In fact, men are most affected by these HPV -related cancers 
compared to women and approximately 5,700 men are diagnosed with these cancers each year in 
the U.S. Research shows that HPV infection can lead to a 6 fold increase in risk for oral cancer, a 
type of HNSCC. Laryngeal papillomatosis is also caused by HPV infection. I  can lead to warts 
in the throat and respiratory areas that cause difficulty breathing and swallowing. This condition 
happens four times more in men than it does in women. Fortunately, if taken prior to HPV 
infection, the HPV vaccine can greatly reduce the chances of these types of cancers. 
 HPV definitely causes health consequences for males, as those described, but by far the 
greatest health burden is cervical cancer in women. HPV contributes to approximately 12,000 
new cervical cancer cases and 4,000 cervical cancer deaths in the United States and 275,000 
cervical cancer deaths worldwide. In fact, cervical cancer is the second most common cancer in 
women in the world. In the U.S., cervical cancer is often prevented because of widesprea and 
affordable screening programs that detect HPV infection in women. However, this screening is 
not available in most parts of the world. Over 85% of cervical cancer deaths are in devloping 
countries where cervical cancer causes the greatest number of female deaths du  to cancer. Keep 
in mind that HPV is sexually transmitted and easily passed from partner to pa tner. Male 
infection can easily spread to female partners which may result in serious female health 
consequences. 
 The HPV vaccine is currently available for boys and men who fall within the 
recommended age range of 9 to 26 years old. It is covered by some, but not all insurance 
companies. This vaccine is exciting because it not only protects you from HPV, but holds great 
promise for preventing a number of serious male health consequences caused by HPV. The 
vaccine is also exciting because it prevents the types of HPV that cause cervical cancer in 
women. Knowing this is not only important for women, but it is important for men too. Because 
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the HPV vaccine offers something referred to as “Herd Immunity,” you, as a man, can play a 
significant role in reducing women’s risk for cervical cancer. 
 Herd immunity is a concept that explains vaccinations and when they work best. 
Basically, an entire community acquires greater immunity to infection if more and more people 
get vaccinated.  As the number of people receiving the vaccine increases, few r people spread 
the infection and therefore the rate of infection decreases overall. This concept is important for 
men considering the HPV vaccine, because if you and other men get vaccinated, immunity will 
spread faster and women will have better protection from getting cervical cancer.  
Ultimately, by taking the HPV vaccine, men like you can contribute to decreasing community 
and worldwide HPV rates, thus reducing cervical cancer worldwide.  Also, you can protect 
yourself from a number of male specific health consequences. Consider how your HPV 
vaccination can protect you from HPV-related illness and help to save female lives in the long 
run.” 
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Appendix K 
 
COLLEGE OF ARTS &  SCIENCES 
DEPARTMENT OF PSYCHOLOGY 
 
Health-Related Decision Making Among Male College Students 
 
Consent Form 
 
 You are invited to participate in a research study called Health-Related Decision Making 
Among Male College Students.  This study is being conducted by Katie Bonafide, a clinic l 
psychology graduate student at Syracuse University, and Dr. Peter Vanable, a professor in the 
Psychology Department.  Involvement in this study is voluntary, so you may choose to 
participate or not. This sheet explains the study requirements and the purpose of the study. Please 
feel free to ask questions about the research if you have any. I will be happy to ex lain anything 
in greater detail if you wish. 
 We are interested in understanding male students’ knowledge, attitudes, and behaviors as 
they relate to health-related decision making. You will be asked to complete a computer-
administered questionnaire that will include items about past sexual experiences, knowledge of 
and attitudes toward sexually transmitted diseases, vaccinations and other health concerns. You 
will also be asked to view a brief health education program on the topic of vaccinations. This 
study will take approximately 1 hour of your time and you will receive 1 hour of research credit 
in exchange for participation. If you choose to withdraw from the study, you will receive partial 
research credit. All information will be kept confidential. In fact, your name will not be linked to 
your survey responses and your participation in the study will be kept confidential.  
The benefit of this research is that you may enhance your awareness of your own 
attitudes and behaviors, and learn valuable information about personal health decisions and 
options. You will also be contributing to research that may ultimately benefit public health 
efforts across the country. The minimal risks associated with study particition include the 
possibility of experiencing embarrassment related to answering questions about sexual health.  
These risks will be minimized by providing you with confidentiality and allowing you to not 
respond to questions you feel uncomfortable answering.  In the event that you do experience 
distress and would like to talk to a counselor or health-care provider, an appropriate referral will 
be provided.  If at any point you no longer wish to continue with the study, you may withdraw 
from the study without penalty or prejudice, and your questionnaire will be discarded. 
If you have any questions about the research or any related concerns, please feel fre to 
contact Katie Bonafide at (315) 443-1052 or Dr. Vanable at (315) 443-1210. If you have 
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additional questions regarding this study or your rights as a research participant, please contact 
the SU Institutional Review Board committee at (315) 443-3013.  
All of my questions have been answered and I have received a copy of this consent frm for my 
own records. I am 18 years or older and I wish to participate in this research study. 
 
 
 
__________________________________________ _________________ 
Signature of Participant      Date 
 
__________________________________________  
Printed name of Participant      
 
__________________________________________ _________________ 
Signature of Investigator      Date 
 
__________________________________________  
Printed name of Investigator       
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Appendix L 
 
Research Assistant Protocol Script 
Study Protocol Script 
 
TO PARTICIPANTS:   “Thank you for participating in this research project.  You will receive 1 
research credit hour for your participation.  Before we begin, please read the study’s consent 
form.  If you have any questions feel free to ask me.  If you don’t have any questions, please sign 
and print your name at the bottom.  I will sign where it indicates name of investigator.” 
 
  Give participant the consent form and answer any questions 
 Using the random assignment table, determine the participant’s assigned condition  
 Assign and record participant’s ID number and the start date and time of the survey 
administration on the study administration log. 
 
“You will be answering a series of questionnaires and be shown a short PowerPoint prese ation 
using a computerized program on this laptop.  Since the program uses written and audio 
presentation, you will need to wear headphones as well. The survey should take about 45 
minutes to complete. If at any point during the survey you have any questions or concerns, please 
ring this bell and I will be right in to assist you. To familiarize yourself with the computer 
program, please complete the following practice exercise.” 
 
 Have participant complete practice CASI questions 
 When prompted to do so on computer, enter the appropriate ID number, survey 
completion date, and RA initials 
 
“Remember that if any questions arise please ring the bell. When you have finish d the survey, 
which will be indicated on the computer screen, please ring the bell to signal your completion.” 
 
 Participant completes survey 
 
“Thank you very much for your participation today.  Before you leave I would like to explain the 
goals of this study.  The goal of this study was to examine the effects of different types of 
informational messages on male college students’ interest in receiving the HPV vaccine. The 
informational presentation you received provided certain facts that might influence HPV 
vaccination decisions. While there was no deception used in this study, some of the questions 
may have been uncomfortable to answer. If you are feeling any distress related to participating in 
this study, this form includes a list of resources available to you for addressing such concerns. 
This form also includes information regarding the HPV vaccine if you would like to learn more. 
Do you have any questions or concerns about the study?” 
 
  Give participant debriefing handout 
  Record participant’s survey completion on study administration log 
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Appendix M 
Debriefing Handout 
Health Related Decision Making Among Male College 
Students 
 
Thank you for participating in this research project!  We appreciate your time and effort in 
participating today!  This project was conducted by Katie Bonafide, a clinical psychology 
graduate student, under the supervision of Dr. Peter Vanable, a clinical psychology faculty 
member.  The goal of this study was to examine the effects of different types of informational 
messages on HPV vaccine interest among male college students. You were randomly assigned to 
receive a specific presentation that contained information that highlighted diff rent benefits of 
receiving the HPV vaccine. Your participation enables researchers to examin  what types of 
information are most effective in encouraging men to consider HPV vaccination.  To protect the 
integrity of the study, we request that you not discuss the purpose of this study with other 
students.  If further questions or concerns arise due to your participation in this study, feel free to 
contact Katie Bonafide at (315) 443-1052, Dr. Vanable at (315) 443-1210 or the Syracuse 
University Institutional Review Board at (315) 443-3013. Thank you again for your 
participation! 
 
Helpful Resources 
 
Syracuse University Health Services  Syracuse University Counseling Ce ter 
111 Waverly Avenue    200 Walnut Place 
 Syracuse NY 13244    Syracuse, NY 13244 
 315-443-9005     315-443-4715 
 
 Psychological Services Center 
 804 University Avenue 
 Syracuse NY 13244 
 315-443-3595 
 
Interested in more information about receiving the HPV vaccine? 
 
Learn more about HPV and the vaccine at: 
 
 The Centers for Disease Control & Prevention (CDC)- HPV and Men Fact Sheet 
http://www.cdc.gov/std/hpv/stdfact-hpv-and-men.htm 
 
 CDC- HPV Vaccines: Questions & Answers 
http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm 
 
 Gardasil- Get the Facts About HPV 
http://www.gardasil.com 
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To find out more about where you can get the vaccine, consult 
your primary care physician, Syracuse University Health 
Services or the Onondaga County Health Department 
 (website:   http://www.ongov.net/health/generalclinics.html  
phone:  315-435-2000) 
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